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ABSTRACT
Phosphorylation of G protein-coupled receptors (GPCRs) by GPCR
kinases (GRKs) and the subsequent recruitment of arrestin is a well-established
paradigm that initiates the process known as desensitization. However, an
emerging theme in GPCR regulation is the possibility of differential regulation
dictated by the phosphorylation pattern elicited by the different members of the
GRK family. Therefore, we have used small interfering RNA-mediated knock
down of the GRKs and arrestins in an attempt to better understand how
phosphorylation regulates the activity and signaling of the M3 muscarinic
acetylcholine receptor (M3 mAChR) and CXCR4, two receptors endogenously
expressed in HEK293 cells.
Using a two-pronged approach of assaying calcium mobilization and ERK
activation, we were able to define and monitor changes in both the G proteindependent and –independent signaling pathways. We found that GRK2, 3, and
6, and arrestin2 and 3 each has a distinct and separable role in regulating the
activity of each receptor. Interestingly, knock down of GRK5 did not effect
signaling via either receptor. Our studies with the M3 mAChR suggest that
signaling is strictly through a G protein-dependent manner and relief of inhibitory
constraints (GRKs and arrestins) subsequently enhances receptor function. In
contrast, CXCR4 uses both a G protein-dependent and –independent (arrestindependent) means of signaling. Notably, arrestin-dependent signaling requires
both GRK3 and 6.
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Based on our studies examining the role of the GRKs in receptormediated signaling, we further characterized agonist-promoted phosphorylation
of CXCR4. Therefore, we created and characterized a cell line stably expressing
Flag CXCR4 to allow for purification of CXCR4 and mass spectrometric analysis.
Importantly, we show that CXCR4 regulation is conserved when stably
overexpressed. Tandem mass spectrometry and phospho-specific antibodies
were used to identify sites of agonist-promoted phosphorylation. These studies
demonstrated that Ser-321, Ser-324, Ser-325, Ser-330, Ser-339 and two sites
between Ser-346-352 were phosphorylated. Use of phospho-specific antibodies,
RNA interference and specific inhibitors revealed that Ser-324/325 was rapidly
phosphorylated by protein kinase C and GRK6 upon agonist treatment while Ser339 was specifically and rapidly phosphorylated by GRK6. Ser-330 also was
phosphorylated by GRK6, albeit with slower kinetics.
Taken together, these results clearly demonstrate that GPCRs are
dynamically regulated by a number of proteins in a coordinated manner and clear
differences exist between receptors expressed within the same cell type. For
CXCR4 specifically, we can now begin to address the functional role of site- and
kinase-specific phosphorylation of CXCR4 in a variety of tissues.

More

importantly, we can also begin to understand whether or not there is altered
regulation of CXCR4 in a variety of diseases.
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CHAPTER I
Introduction
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G PROTEIN-COUPLED RECEPTORS
Cellular homeostasis is maintained through an organism’s ability to
transduce a large number of extracellular stimuli into intracellular signaling
cascades through interactions with proteins spanning the cellular membrane.
One of the largest families of these cell surface proteins is the G protein-coupled
receptors (GPCRs) (Pierce et al., 2002), comprising ~3% of the human genome
and encoding for greater than 800 receptors (Bai, 2004). GPCRs bind to a wide
variety of extracellular ligands including biogenic amines, amino acids, peptides,
photons, and odorants resulting in diverse cellular responses such as
proliferation, differentiation, cell survival, and cell motility (Marinissen and
Gutkind, 2001).
Based on their primary amino acid sequence, GPCRs were predicted to
contain seven transmembrane spanning α-helices connected by alternating
intracellular and extracellular loops (Hargrave and McDowell, 1992), which was
confirmed by the crystal structures of both rhodopsin (Palczewski et al., 2000)
and the β2-adrenergic receptor (β2AR) (Rasmussen et al., 2007).

The N-

terminus, extracellular loops, and transmembrane domains are involved in ligand
binding, while the intracellular loops and C-terminus are involved in signaling and
receptor regulation. Despite sharing the same topology, GPCRs are further
subdivided based on conserved structural features and amino acid motifs into
five families: glutamate, rhodopsin, adhesion, fizzled/taste, and secretin
(Fredriksson et al., 2003). The rhodopsin family constitute ~90% of all GPCRs
and is the most well studied class of GPCRs (Fredriksson et al., 2003).
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Signal Transduction by GPCRs
GPCRs respond to a myriad of extracellular stimuli, converting these cues
into distinct intracellular signaling events (Figure 1). As the name implies,
GPCRs couple to and activate the heterotrimeric family of guanine nucleotide
binding proteins (G proteins), which consist of Gα, which contains the nucleotide
binding pocket, and the functional heterodimer of Gβγ (Oldham and Hamm,
2008). In the inactive state, Gα is bound to guanosine diphosphate (GDP) and
complexed with Gβγ. Upon ligand binding, GPCRs undergo a conformational
change that allows them to act as a guanine nucleotide exchange factor (GEF)
and catalyze the exchange of GDP for guanosine triphosphate (GTP) on the Gα
subunit. This causes a conformational change of the Gα subunit, resulting in the
dissociation of the heterotrimer into Gα and Gβγ and the subsequent activation of
a number of second messenger effectors such as adenylyl cyclase (AC),
phospholipase C isoforms (PLC), and ion channels (Flower, 1999; Marinissen
and Gutkind, 2001). The G proteins are molecular switches, and through the
hydrolysis of GTP to GDP, return to the inactive state. The Gα subunit has
intrinsic, albeit slow, GTPase activity. Therefore, proteins known as regulators of
G protein signaling (RGS) (Willars, 2006) act as GTPase activating proteins
(GAPs) and catalyze the hydrolysis of GTP to GDP, thereby shutting off signaling
and allowing the heterotrimer to re-associate.
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Figure 1. Signal transduction by GPCRs
GPCRs bind to a number of extracellular stimuli including biogenic amines,
amino acids, lipids, proteins, photons and odorants leading to activation of the
heterotrimeric G proteins. Exchange of GDP for GTP in the nucleotide-binding
pocket of Gα subunits results in activation and dissociation of the heterotrimer
into Gα and Gβγ subunits. The dissociated heterotrimer is then able to interact
with and activate a number of effectors and signaling pathways that ultimately
result in cellular responses such as proliferation, differentiation, cell survival and
cell motility.
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The Heterotrimeric G Proteins
As described above, there are three subunits that comprise the
heterotrimeric G proteins: Gα, Gβ, and Gγ. There are currently 16 different Gα
subunits, subdivided into four different classes based on sequence homology:
Gαs, Gα i, Gα q, and Gα12/13 (McCudden et al., 2005; Simon et al., 1991). All Gα
proteins, with the exception of the photoreceptor-specific Gαt, are N-terminally
modified with palmitate, a 16-carbon fatty acid. The Gαi class is additionally
modified with myristate, a 14-carbon saturated fatty acid. These fatty acid
modifications are important for membrane localization of the Gα subunits
(McCudden et al., 2005). Each class of Gα subunits has well known and
characterized cellular targets, known as effectors. The Gαs class stimulates the
activity of AC, increasing the intracellular concentration of cyclic adenosine
monophosphate (cAMP) (Ross and Gilman, 1977). The Gαi class, initially
identified for its ability to inhibit AC activity (Hildebrandt and Birnbaumer, 1983),
has a growing list of effectors that includes phosphodiesterases and
phospholipases and are critical for sensory transduction (McCudden et al., 2005).
The Gαq class activates PLC resulting in the subsequent generation of the
second messengers diacylglycerol (DAG) and inositol trisphosphate (IP3) (Rhee,
2001).

Finally, the Gα12/13 class stimulates the activity of the RhoGEFs

(McCudden et al., 2005).
There is nearly as much diversity amongst the Gβ and Gγ subunits.
Currently, there are 5 Gβ and 12 Gγ subunits, which creates the possibility for
forming a large number of Gβγ heterodimers (McCudden et al., 2005). All Gγ
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subunits are prenylated post-translationally, with either a 15-carbon farnesyl
group or a 20-carbon geranylgeranyl group added to a C-terminal CAAX motif.
Similar to the Gα subunits, this modification is critical for the membrane
localization of Gβγ. Gβγ is a functional heterodimer and is able to activate a
number of effectors following dissociation from Gα. The first effectors identified
were the G-protein-regulated inward-rectifier K+ channels (GIRK or Kir3 channels)
(Logothetis et al., 1987). Since then, Gβγ has been shown to activate a number
of other effectors including PLC-β and -ε (Boyer et al., 1992; Wing et al., 2001),
phosphoinositide-3’ kinase-γ (PI3Kγ) (Stephens et al., 1994), and various AC
isoforms (Tang and Gilman, 1991).
GPCRs constitute one of the largest families of cell surface receptors and
are critically involved in many aspects of biology. Currently, GPCRs are targeted
by ~30% of marketed drugs (Jacoby et al., 2006) and as more and more GPCRs
are found to be involved in various pathologies such as cancer, HIV, and
cardiovascular disease, a better understanding of the molecular mechanisms
regulating receptor activity and signaling is needed.
REGULATION OF GPCRs BY G PROTEIN-COUPLED RECEPTOR KINASES
AND ARRESTINS
The activity of GPCRs is tightly regulated to ensure the proper magnitude
and duration of signaling cascades within the cell. There are three principal
modes of GPCR regulation: desensitization, where receptors become refractory
to continued stimulation; internalization, a process that removes receptors from
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the cell surface; and down regulation, where receptors are trafficked to
lysosomes for degradation (Figure 2).

Homologous and Heterologous Desensitzation
Desensitization is a critical step in GPCR regulation, effectively shutting off
receptor signaling. The process is initiated by phosphorylation of intracellular
serine/threonine residues and is classified as either heterologous (agonistindependent) or homologous (agonist-dependent). Heterologous desensitization
is typically mediated by the second messenger kinases, protein kinase A (PKA)
and protein kinase C (PKC), which are activated by a number of cellular stimuli
including receptor tyrosine kinases (RTKs) and GPCRs (Ferguson, 2001).
Phosphorylation is therefore agonist-independent and results in a decreased
affinity of the GPCR-G protein interaction. Homologous desensitization, on the
other hand, is classically mediated by G protein-coupled receptor kinases
(GRKs). Unlike second messenger kinases, GRKs specifically phosphorylate the
activated, agonist-occupied form of the receptor and this usually results in the
recruitment of the arrestin family of proteins (Krupnick and Benovic, 1998).
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Figure 2. Regulation of GPCRs by GRKs and Arrestins
Upon receptor activation, GRKs phosphorylate serine/threonine residues of the
third intracellular loop and C terminal tail, initiating the process of desensitization.
Arrestins are then recruited to and bind the activated, phosphorylated receptor,
uncoupling it from G protein and terminating signaling. Additionally, the arrestins
act as adaptor proteins and complex with clathrin and AP-2 to target the
receptors to clathrin-coated pits for internalization.

In the endosomal

compartment, ligand dissociates and the receptors are dephopshorylated. The
receptors are then either sorted to the lysosome for degradation (down
regulation) or recycled back to the plasma membrane (resensitization).
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G Protein-Coupled Receptor Kinases
There are currently 7 members of the GRK family, which are divided into
three subfamilies based on sequence homology: (i) GRK1 (rhodopsin kinase)
(Shichi and Somers, 1978; Lorenz et al., 1991) and GRK7 (Weiss et al., 1998);
(ii) GRK2 (β-adrenergic receptor kinase 1, βARK1) (Benovic et al., 1986; Benovic
et al., 1989) and GRK3 (β-adrenergic receptor kinase 2, βARK2) (Benovic et al.,
1991); and (iii) GRK4 (Ambrose et al., 1992), GRK5 (Kunapuli and Benovic,
1993), and GRK6 (Benovic and Gomez, 1993).

GRK2, 3, 5 and 6 are

ubiquitously expressed and have the ability to interact with and phosphorylate
various GPCRs. Conversely, GRK1, 4, and 7 have a more restricted pattern of
expression, being limited to the retina (GRK1 and 7) or the brain, testis, and
kidneys (GRK4) (Krupnick and Benovic, 1998).
The overall topology of the GRKs is conserved among the subfamilies,
with a moderately conserved N-terminal domain, a highly conserved central
catalytic domain, and variable C-terminal domain (Krupnick and Benovic, 1998).
The central catalytic domain promotes phosphorylation of a variety of substrates
and is most closely related to the PKA/PKC family of kinases (Hanks and Hunter,
1995). The N-terminus of GRK is thought to not only mediate the interaction with
substrates (Palczewski et al., 1991; Pronin et al., 1997), but also result in full
activation of the kinase (Pao and Benovic, 2005). The GRKs also contain a
RGS-like domain within the N terminus (Siderovski et al., 1996). However, to
date, only GRK2 and 3 have been shown to bind to Gα subunits in an aluminum
fluoride (AlF4-) dependent manner (Carman et al., 1999b). This interaction
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occurs via a region that is unique to GRK2 and 3 (Sterne-Marr et al., 2003), and
regulates Gαq without enhancing its GTPase activity (Carman et al., 1999b;
Sallese et al., 2000), demonstrating a novel, phosphorylation-independent means
of GPCR regulation. The N-terminus of the GRK4 family has a unique, highly
conserved, phosphatidylinositol (4,5)-bisphosphate (PIP2) binding site, which
may function to enhance the catalytic activity of the kinases (Pitcher et al., 1996).
The most divergent region of the GRKs is the C-terminal domain, which is
responsible for membrane localization (Penn et al., 2000). GRK1, 2, and 3 are
predominantly cytoplasmic, needing to translocate to the membrane upon
receptor activation. GRK1 is post-translationally modified by farnesylation of a Cterminal CAAX motif and recruited to the plasma membrane upon rhodopsin
activation (Inglese et al., 1992). GRK2 and 3 contain both a pleckstrin homology
(PH) domain and a Gβγ binding site (Pitcher et al., 1992; Pitcher et al., 1995).
The concomitant interaction with PIP2 and free Gβγ targets the kinases to the
plasma membrane upon receptor activation. In contrast, GRK4 through GRK7
are constitutively associated with the plasma membrane. GRK4 and 6 maintain
their plasma membrane localization through palmitoylation of one or more Cterminal cysteine residues (Premont et al., 1996; Stoffel et al., 1994). GRK5 is
predominantly associated with the plasma membrane through electrostatic
interactions between a polybasic region and membrane phospholipids (Pitcher et
al., 1996). Finally, similar to GRK1, GRK7 contains a C-terminal CAAX motif.
However, in contrast to GRK1, GRK7 is post-translationally modified with a

12

geranylgeranyl group and thereby constitutively associated with the plasma
membrane (Weiss et al., 2001).
Regulation of GRK Activity
In addition to membrane recruitment and activation by GPCRs, the activity
of the GRKs can be modulated by a number of intracellular molecules including
phospholipids, site-specific phosphorylation, and protein/protein interactions
(Penela et al., 2003). The GRKs are lipid-dependent enzymes. Interactions with
PIP2 and other acidic phospholipids (e.g., phosphatidylserine (PS)) enhances the
ability of GRK2 to phosphorylate membrane-bound receptors as well as soluble
substrates (DebBurman et al., 1996; DebBurman et al., 1995; Pitcher et al.,
1995). Interestingly, PIP2 also inhibited GRK2-mediated phosphorylation of
agonist-occupied M2 muscarinic acetylcholine receptor if used at high
micromolar concentrations or in the absence of Gβγ (DebBurman et al., 1996;
DebBurman et al., 1995). GRK5 has two phospholipid binding domains, in the Nand C-terminus, which are highly conserved among the GRK4 subfamily of
kinases. The N-terminal binding site shows a great deal of specificity for PIP2,
which enhances GRK5-mediated receptor phosphorylation without affecting
autophosphorylation or phosphorylation of soluble substrates (Pitcher et al.,
1996). The C-terminal binding site, which shows little lipid specificity, enhances
GRK5 autophosphorylation and activity towards a number of different substrates
(Kunapuli et al., 1994; Pronin et al., 1998).
A number of protein kinases are able to phosphorylate the GRKs, thereby
modulating their cellular localization and catalytic activity.
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PKA-mediated

phosphorylation of GRK2 on Ser685 increases its affinity for Gβγ and enhances
plasma membrane translocation and receptor phosphorylation (Cong et al.,
2001). Similarly, PKC-mediated phosphorylation of GRK2 on Ser29 enhances
membrane recruitment and receptor phosphorylation (Winstel et al., 1996).

In

contrast, the catalytic activity of GRK5 is drastically inhibited by PKC-mediated
phosphorylation of two C-terminal serine residues (Pronin and Benovic, 1997a).
Interestingly, this region of GRK5 also contains inhibitory autophosphorylation
sites (Pronin et al., 1998). In addition to the second messenger kinases, GRK2
is phosphorylated by both c-Src and extracellular signal-regulated kinase (ERK).
c-Src, a tyrosine kinase, phosphorylates and enhances the activity of GRK2
towards both receptor and soluble substrates (Fan et al., 2001; Sarnago et al.,
1999).

In addition, c-Src phosphorylation also plays a critical role in the

degradation of GRK2 (Penela et al., 2001). In contrast, ERK phosphorylates
GRK2 on Ser670 and impairs both Gβγ binding and catalytic activity (Pitcher et
al., 1999).
The calcium binding proteins recoverin and calmodulin are also important
regulators of the GRK activity. Recoverin, which is present in photoreceptor
cells, is able to bind to and inhibit the activity of GRK1 (Klenchin et al., 1995).
Calmodulin is able to inhibit the activity of GRK2, 3, 5, and 6, however, it is highly
specific for GRK5 and 6 (Pronin et al., 1997b). The calmodulin binding sites
have been mapped to both the N and C terminal domains of GRK5, which
disrupts membrane association, substrate phosphorylation and enhances
inhibitory autophosphorylation (Pronin et al., 1998; Pronin et al., 1997b). Finally,
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the activity of the GRKs is inhibited through interactions with caveolin and αactinin, which may be a way to suppress GRK activity in particular microdomains
(Carman et al., 1999a; Freeman et al., 2000).
Arrestins
The arrestins are a family of proteins classically involved in shutting off
signaling by binding to activated, phosphorylated GPCRs and uncoupling them
from their cognate G protein (Krupnick and Benovic, 1998). However, their
biological functions are ever expanding and the arrestins are now known to
regulate receptor internalization, G protein independent signaling, and gene
expression (DeWire et al., 2007; Moore et al., 2007).
In mammals, there are four members of the arrestin family that have been
cloned and characterized.

Based on function, localization and sequence

homology, they are subdivided into two groups: the visual arrestins (arrestin1 and
4), and the non-visual arrestins (arrestin2 and 3, also known as β-arrestin1 and
2). Arrestin1, originally termed S-antigen, was found to translocate from the
cytosol to rod outer segments (ROS) upon rhodopsin activation and regulate light
dependent signal transduction (Kuhn et al., 1984; Pfister et al., 1985).
Purification of arrestin1 allowed for the subsequent cloning of a bovine arrestin1
and of arrestin4 (Murakami et al., 1993; Shinohara et al., 1987; Yamaki et al.,
1987). As arrestin1 and arrestin4 are restricted to the visual system, they are
believed to exclusively regulate photoreceptor GPCRs (Krupnick and Benovic,
1998). The existence of a non-visual arrestin was initially postulated during
studies examining the regulation of the β2AR by GRK2 (Benovic et al., 1987).
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The ability of GRK2 to desensitize purified β 2AR became attenuated as the
GRK2 preparations became more homogenous, suggesting the loss of an
important cofactor for β2AR desensitization. Desensitization was restored by the
addition of arrestin1, albeit at very high concentrations (Benovic et al., 1987).
Subsequently, a protein termed β-arrestin (arrestin2) was cloned, which shared
high homology and function to arrestin1 (Lohse et al., 1990). Unlike arrestin1,
arrestin2 is not restricted to one particular tissue, but is ubiquitously expressed.
Soon thereafter, a second ubiquitously expressed non-visual arrestin was cloned
and termed β-arrestin2 (arrestin3) (Attramadal et al., 1992). The ubiquitous
nature of arrestin2 and 3 suggest that they are involved in the regulation of a
number of GPCRs.
Importantly, arrestins are able to recognize both the activation and
phosphorylation state of GPCRs, suggesting that they recognize domains
specifically exposed upon receptor activation. Studies have determined that the
N terminal domain of arrestin is involved in receptor recognition of a number of
GPCRs (Gurevich and Benovic, 1993a; Gurevich et al., 1995; Gurevich et al.,
1993b). Extensive mutagenesis of arrestin1 has mapped the phosphorylation
recognition domain to residues 158-185 (Gurevich and Benovic, 1993a).
Subsequently, three residues (Arg171, Arg175, and Lys176) were found to be
critical for the interaction with phosphorylated rhodopsin (Kieselbach et al.,
1994). Interestingly, neutralization or charge reversal of Arg175 resulted in
phosphorylation-independent binding to light activated rhodopsin, suggesting that
this region acts as phospho-sensitive switch (Gurevich and Benovic, 1993a).
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Mutation of the corresponding residue in arrestin2 (Arg169) to glutamate,
resulted in a similar phosphorylation-independent binding to the β2AR (Kovoor et
al., 1999).

Based on these and other studies, it is thought that arrestin

undergoes a conformational change upon binding to activated, phosphorylated
receptors exposing regions that allows them to interact with a number of other
proteins (Gurevich and Gurevich, 2006).
The Role of Arrestins in Receptor Desensitization and Trafficking
The arrestins are classically known to shut off, or “arrest”, GPCRmediated signaling events through their ability to bind to activated,
phosphorylated receptors and uncouple them from their cognate G protein
(Krupnick and Benovic, 1998).

Moreover, arrestins interact with cAMP

phosphodiesterases (Perry et al., 2002) and diacylglycerol kinases (Nelson et al.,
2007), allowing them to dually desensitize GPCRs via Gs and Gq uncoupling as
well as enhancing the rate of cAMP degradation and PIP2 regeneration,
respectively.
Following desensitization, activated GPCRs are removed from the cell
surface by a process known as internalization. The most common route for
GPCR internalization is through specialized microdomains known as clathrin
coated pits (CCPs), although other mechanisms do exist (Marchese et al.,
2003a). A role for arrestin in receptor internalization was first demonstrated in
studies using a mutated β 2AR that was impaired in agonist induced
phosphorylation and internalization (Ferguson et al., 1996). Overexpression of
either arrestin2 or 3 was able to promote internalization of this receptor whereas
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various arrestin mutants inhibited internalization of the β2AR. Mechanistic insight
into this arrestin-mediated internalization was gained from the observations that
arrestin2 and 3 directly interact with clathrin (Goodman et al., 1996), clathrin
associated protein (AP)-2 (Laporte et al., 2000; Kim and Benovic, 2002), and
phosphoinositides, which is critical for targeting GPCRs to CCPs (Gaidarov et al.,
1999).
Once internalized, receptors can either be recycled to the plasma
membrane in a process known as resensitization or trafficked to the lysosomes in
a process known as down regulation (Marchese et al., 2008).

While the

molecular mechanisms mediating differential sorting of GPCRs are not well
established, the stability of the GPCR/arrestin complex may be a contributing
factor. For example, GPCRs have been separated into “Class A” and “Class B”
receptors based on how they interact with the non-visual arrestins (Oakley et al.,
2001). Class A receptors (e.g., β2AR) transiently associate with the non-visual
arrestins, which may allow for rapid dephopshorylation and recycling back to the
plasma membrane, essentially resetting the system. Class B receptors (e.g.,
angiotensin 1a receptor (AT1aR)) form stable complexes with the non-visual
arrestins and co-traffic into endosomes.

This stable association has been

proposed to sterically hinder dephosphorylation and prevent receptor
resensitization (Oakley et al., 2001). Additionally, arrestin2 has been shown to
be critical for the lysosomal sorting of CXCR4 (Bhandari et al., 2007), a GPCR
known to undergo agonist-induced down regulation (Marchese and Benovic,
2001).
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The Role of Arrestins in GPCR Signaling
Studies over the past several years have elucidated a novel role for the
arrestins: acting as scaffolds for activation of a number of signaling pathways,
also known as G protein-independent signaling. Initial evidence for arrestinmediated signaling came from results showing that a dominant negative form of
arrestin, which blocks internalization, inhibited full activation of ERK1/2 (Daaka et
al., 1998). Soon thereafter, arrestin was shown to interact with c-Src, linking this
non-receptor tyrosine kinase to GPCR-mediated signaling (DeFea et al., 2000a;
Luttrell et al., 1999). Subsequent studies revealed that arrestin was able to
scaffold specific components of the mitogen activated protein kinase (MAPK)
cascade including Raf-1, MEK1, ERK1/2 (DeFea et al., 2000b; Luttrell et al.,
2001) and JNK3 (McDonald et al., 2000). Though no direct interaction has ever
been established, p38 activation has been shown to be arrestin dependent
following activation of a number of different GPCRs (Bruchas et al., 2006; Miller
et al., 2003; Sun et al., 2002).
Certain ligands appear to have the ability to preferentially activate a
particular downstream signaling pathway, a phenomenon known as biased
agonism. For GPCRs, this would mean preferential activation of either a G
protein-dependent or –independent pathway. This was first identified for the
AT1aR using a specific mutant of the ligand angiotensin, known as AngII(SII).
This mutant ligand was unable to activate G protein-dependent signaling (i.e.,
phosphoinositide (PI) hydrolysis) but was able to activate ERK1/2 in an arrestindependent manner (Wei et al., 2003). Similar mechanisms have been uncovered
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for both the vasopressin and β2 adrenergic receptors (Azzi et al., 2003; Drake et
al., 2008; Wisler et al., 2007).

THE CHEMOKINE RECEPTOR CXCR4
Chemokines are 8-10 kDa cytokines that are classified into four groups
(CXC, CC, C, and CX3C) based on the position of the first two cysteines (Zlotnik
and Yoshie, 2000). Chemokine receptors belong to the GPCR superfamily and
couple to the pertussis toxin sensitive Gi proteins (Murphy et al., 2000). In
general, chemokines/chemokine receptors exhibit promiscuity, being able to bind
multiple receptors/ligands, though 6 of the 18 chemokine receptors bind a single
ligand (Balkwill, 2004a). One of the best studied chemokine receptors is CXCR4,
primarily due to its role as a co-receptor for HIV entry (Feng et al., 1996) as well
as its ability to mediate the metastasis of a variety of cancers (Zlotnik, 2006b).
CXCR4 is a 352 amino acid rhodopsin-like GPCR and selectively binds
the CXC chemokine Stromal Cell-Derived Factor 1 (SDF-1) also known as
CXCL12 (Fredriksson et al., 2003; Murphy et al., 2000). Classically, two
alternatively spliced isoforms of SDF have been identified. SDF-1α is an 89
amino acid protein that is the predominantly expressed form of SDF-1 while SDF1β contains a four amino acid extension at the carboxyl terminus (Shirozu et al.,
1995). SDF-1α and β bind to CXCR4 with a comparable affinity (Kd of 7.5 and
13.7 nM, respectively) (Hesselgesser et al., 1998). Recently, an additional four
splice variants that contain 30 (SDF-1γ), 31 (SDF-1δ), 1 (SDF-1ε), and 51 (SDF1φ) amino acid extensions at the carboxyl terminus compared to SDF-1α have
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been identified (Yu et al., 2006). Each of these isoforms stimulates cell migration
in a CXCR4-dependent manner. However, as they have a differential tissue
distribution, their functional significance is currently unknown. Mice that lack
either SDF-1 or CXCR4 exhibit an almost identical phenotype of late gestational
lethality and defects in B cell lymphopoiesis, bone marrow colonization, and
cardiac septum formation (Nagasawa et al., 1996; Zou et al., 1998). These and
other studies reveal that CXCR4 is essential for development, hematopoeisis,
organogenesis, and vascularization (Ma et al., 1998; McGrath et al., 1999;
Nagasawa et al., 1996; Nagasawa et al., 1998; Tachibana et al., 1998; Zou et al.,
1998), in addition to functioning as a classical chemokine receptor (i.e., directed
chemotaxis) in the adult (Moser and Loetscher, 2001; Murphy, 1994).
Given that CXCR4 plays a prominent role in HIV (Agrawal et al., 2006;
Lusso, 2006; Reeves and Piefer, 2005) and cancer metastasis (Burger and
Kipps, 2006; Kucia et al., 2005; Zlotnik, 2006a; Zlotnik, 2006b), the knowledge of
the factors that shape signaling, receptor regulation, and receptor expression,
and how dysregulation of these pathways may contribute to disease progression
is crucial.

REGULATION OF CXCR4 EXPRESSION AND FUNCTION
Transcriptional Control of CXCR4
In order to understand the role of CXCR4 in disease, a fundamental
understanding of the factors regulating expression is critical. While CXCR4 was
initially cloned from leukocytes (Loetscher et al., 1994; Nomura et al., 1993), it
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has since been shown to be expressed in a number of tissues in addition to cells
of hematopoetic lineages (Rossi and Zlotnik, 2000). The promoter region of
CXCR4 contains a number of predicted regulatory consensus sequences (Caruz
et al., 1998; Moriuchi et al., 1997; Wegner et al., 1998), however, the basal
transcription is mainly controlled by the opposing actions of two transcriptional
regulators. Functional characterization of the CXCR4 promoter has revealed that
Nuclear Respiratory Factor-1 (NRF-1) is the major transcription factor positively
regulating the transcription of CXCR4 (Moriuchi et al., 1997; Wegner et al.,
1998), although a potential role for an additional transcription factor, SP-1, has
also been suggested (Wegner et al., 1998). This work also defined a negative
regulatory element upstream (near position –300 of the transcriptional start site)
that may be mediated by Ying Yang 1 (YY1) (Moriuchi et al., 1999b).
In addition to the basal regulation of CXCR4 transcription, a number of
signaling molecules also have been shown to affect CXCR4 transcription. For
example, the expression of CXCR4 can be increased as a result of intracellular
second messengers such as calcium (Moriuchi et al., 1997) and cyclic AMP
(Cristillo et al., 2002), by the cytokines interleukin-2 (IL-2) (Moriuchi et al., 1997),
IL-4 (Jourdan et al., 2000), IL-7 (Jourdan et al., 2000), IL-10 (Wang et al., 2001),
IL-15 (Jourdan et al., 2000), TGF-1β (Wang et al., 2001), and simultaneous CD3
and CD28 engagement (Moriuchi et al., 1997), and by growth factors such as
basic fibroblast growth factor (bFGF) (Feil and Augustin, 1998; Salcedo et al.,
1999), vascular endothelial growth factor (VEGF) (Salcedo et al., 1999), and
epidermal growth factor (EGF) (Phillips et al., 2005).

22

On the other hand,

inflammatory cytokines such as tumor necrosis factor-α (TNF-α) (Feil and
Augustin, 1998; Gupta et al., 1998; Han et al., 2001), interferon-γ (INF-γ) (Gupta
et al., 1998), and IL-1β (Gupta et al., 1998) have all been shown to attenuate
CXCR4 expression.
These data clearly show that there is dynamic regulation of CXCR4
transcription as the result of physiological stimuli. Of additional interest are those
factors that regulate CXCR4 expression and affect disease progression, such as
modulating HIV infection. Alterations in NRF-1 or YY1 activity can lead to an
increase or decrease in transcription of CXCR4, respectively, which certain
viruses appear to have taken advantage of. The human T lymphotropic virus type
I transactivator Tax protein interacts with and enhances NRF-1 activity, which in
infected individuals may enhance susceptibility to HIV infection or disease
progression (Moriuchi et al., 1999a). In contrast, individuals infected with human
herpes virus 6 have a decrease in cell surface expression of CXCR4 (Yasukawa
et al., 1999). Investigation into the underlying mechanism has revealed that there
is an increase in YY1 binding through a decreased association with c-Myc, a
natural suppressor of YY1 activity (Hasegawa et al., 2001).
Regulation of CXCR4 Protein Expression
A number of co-translational modifications contribute to the expression
and function of CXCR4. Within the extracellular domain of CXCR4, there are two
potential N-linked glycosylation sites, Asn11 and Asn176 (Berson et al., 1996).
Both sites undergo glycosylation when CXCR4 is expressed in Sf9 insect cells
(Zhou and Tai, 1999), however, only Asn11 appears to be glycosylated in
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mammalian cells (Chabot et al., 2000). SDF and the HIV-1 glycoprotein gp120
bind to a non-overlapping region of the N-terminus of CXCR4 (Brelot et al., 2000;
Brelot et al., 1997; Chabot et al., 1999; Doranz et al., 1999; Kajumo et al., 2000;
Zhou et al., 2001) and glycosylation has opposing effects on each process.
Mutation of Asn11 to glutamine leads to enhanced CD4-dependent binding of
both CXCR4-specific and duel tropic (CCR5 and CXCR4) HIV-1 isolates (Brelot
et al., 1997; Thordsen et al., 2002; Wang et al., 2004). Conversely, mutation of
Asn11 to glutamine (Wang et al., 2004) or leucine (Zhou and Tai, 1999) disrupts
SDF binding and diminishes signal transduction (Wang et al., 2004). Thus,
glycosylation of CXCR4 is important for SDF binding and helps to inhibit the use
of CXCR4 as an HIV-1 co-receptor.
CXCR4 has also been shown to undergo tyrosine sulfation, a modification
catalyzed by tyrosyl protein sulfotransferase within the trans-golgi network.
There are three extracellular tyrosines in CXCR4 that are modified by sulfation,
Tyr7, Tyr12, and Tyr21, with Tyr21 accounting for the majority of sulfate
incorporation (Farzan et al., 2002a). Functionally, tyrosine sulfation of CXCR4
doesn’t regulate co-receptor usage by HIV-1 (Farzan et al., 2002a) as is
observed with CCR5 (Farzan et al., 1999), however, similar to CCR2b
(Preobrazhensky et al., 2000), CCR5 (Farzan et al., 2002b), and CX3CR1 (Fong
et al., 2002a), this is an important modification for ligand binding (Farzan et al.,
2002a). Indeed, the structural basis for sulfotyrosine-SDF interaction reveals that
sulfotyrosine 21 binds to a specific site on SDF-1 that includes Arg47, while
sulfotyrosine 7 and 12 occupy positively charged clefts of a SDF homodimer
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(Veldkamp et al., 2008; Veldkamp et al., 2006).

An additional N-terminal

modification that has been identified in CXCR4 is addition of a chondroitin sulfate
chain at serine 18, although no functional consequence of this modification has
been identified (Farzan et al., 2002a).
Oligomerization
An emerging theme in GPCR signaling is the formation of homo- and
heterodimers (Angers et al., 2002). CXCR4 exhibits significant heterogeneity in
cells, which may be a result of ubiquitination, differential glycosylation, or the
formation of oligomers (Lapham et al., 2002; Sloane et al., 2005). It’s been
suggested that CXCR4 has the ability to homodimerize in the absence of ligand
(Babcock et al., 2003; Issafras et al., 2002; Percherancier et al., 2005; Toth et al.,
2004), an event that most likely occurs soon after protein translation (Babcock et
al., 2003). However, two reports suggest that SDF can also enhance dimerization
(Toth et al., 2004; Vila-Coro et al., 1999). Interestingly, CXCR4 homodimers
have been suggested to form between wild type and C terminally truncated
mutations of CXCR4 in patients with WHIM syndrome, effectively enhancing the
activity of the wild type receptor (Lagane et al., 2008). There have also been
reports of CXCR4 forming heterodimers with CCR2, T cell receptors, and CD4,
which may affect the functionality of CXCR4 as a co-receptor for HIV
(Basmaciogullari et al., 2006; Kumar et al., 2006; Mellado et al., 1999;
Percherancier et al., 2005; Rodriguez-Frade et al., 2004; Toth et al., 2004).
Recently, heterodimerization between CXCR4 and the delta opioid receptor in
immune cells has been shown to functionally inactivate each receptor, providing
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another layer of potential regulation of GPCR activity (Pello et al., 2008). Finally,
while some studies suggest that CXCR4 does not heterodimerize with CCR5
(Babcock et al., 2003; Issafras et al., 2002), CD4+ cells isolated from patients
with a CCR5Δ32 mutant, a loss-of function mutation that prevents cell surface
expression of CCR5, have reduced expression of CXCR4 (Agrawal et al., 2004).
Moreover, these studies show that CCR5Δ32 and CXCR4 can interact resulting
in reduced cell surface expression of CXCR4 and enhanced resistance to HIV
infection (Agrawal et al., 2004). More recently, it has been shown that CXCR4
and CCR5 form heterodimers at the immunological synapse, having a specific
function and affecting T cell responses to antigen (Contento et al., 2008).
The functional consequences of homo- or heterodimerization of GPCRs
are currently not well understood. However, it has been suggested that
homodimerization of CXCR4 is necessary to elicit G protein independent
activation of JAK/STAT as well as enhance the response of CXCR4 to SDF (see
below). Heterodimerization may be a means of achieving an additional level of
regulation.

For example, it has recently been proposed that non-agonist

occupied CCR5 may be phosphorylated by GRK2 activated as a result of
heterodimer formation and activation of C5a (Huttenrauch et al., 2005). Taken
together, homo- and hetero-oligomerization of CXCR4 may be a way of
regulating signaling while also allowing for alternative, non-classical, signaling
pathways upon activation.
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REGULATION OF CXCR4 SIGNALING
SDF Binding
The interaction between SDF and CXCR4 has been proposed to occur
through a two-step process (Crump et al., 1997). The initial interaction between
residues 12-17 of SDF and 2-36 of CXCR4 are believed to result in a
conformational change in the receptor (Huang et al., 2003). This conformational
change facilitates interaction between the first eight amino acids of SDF and an
exposed binding pocket in CXCR4 that involves residues in both the second
(Asp187) and third (Glu268) extracellular loops (Brelot et al., 2000; Zhou et al.,
2001). As this interaction requires the integrity of both SDF and CXCR4, it is not
surprising that proteases are able to inhibit this interaction. During an
inflammatory response, neutrophil released cathepsin G and neutrophil elastase
have the ability to inactivate SDF by cleaving the N-terminal residues necessary
for interacting with CXCR4 (Delgado et al., 2001; Valenzuela-Fernandez et al.,
2002). Additionally, the widely expressed cell surface protease dipeptidase 26
(CD26) is also able to cleave and inactivate SDF (Christopherson et al., 2002;
Huhn et al., 2000; Lambeir et al., 2001). To date, only neutrophil elastase has
been shown to cleave the N terminal domain of CXCR4, effectively disrupting
interaction with SDF (Valenzuela-Fernandez et al., 2002). Therefore,
inflammatory responses promote the release of factors that positively and
negatively regulate the receptor. When taken together, these data highlight the
exquisite interplay between a variety of factors that are able to shape and
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influence the SDF-CXCR4 signaling axis, ensuring that the proper physiological
response is elicited.
SDF-1 is also able to interact with glycosaminoglycans, such as heparin
sulfate, and is most likely immobilized in vivo allowing for gradient formation
(Hoogewerf et al., 1997; Tanaka et al., 1993). Furthermore, this association may
induce the oligomerization of SDF-1 (Sadir et al., 2001), a phenomenon
observed at high SDF-1 concentrations (Crump et al., 1997; Dealwis et al., 1998;
Fernandez and Lolis, 2002; Holmes et al., 2001), that may promote CXCR4
oligomerization and enhanced function. In fact, it has been shown that the
combination of glycosaminoglycans and SDF-1 enhanced migration when
compared to SDF alone (Netelenbos et al., 2002). Moreover, SDF-1 mediated
inhibition of HIV X4 isolates was enhanced in the presence of heparin sulfate
(Valenzuela-Fernandez et al., 2001). Interestingly, it has been recently shown
that a constitutive homodimer of SDF-1 completely inhibits CXCR4-mediated
chemotaxis without affecting calcium mobilization, suggesting that SDF
dimerization may preferentially activate certain signaling pathways (Veldkamp et
al., 2008).
It may also be possible to sensitize CXCR4 to have a greater response to
lower SDF-1 concentrations. Recent evidence suggests that products released
during inflammatory responses (Majka et al., 2000) or platelet activation
(Janowska-Wieczorek et al., 2001; Wysoczynski et al., 2005) “prime” the SDF
response enhancing hematopoetic stem/progenitor cell migration at lower SDF
concentrations (Janowska-Wieczorek et al., 2001; Majka et al., 2000;
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Wysoczynski et al., 2005). This phenomenon may be the result of changing the
membrane localization of CXCR4 through incorporation into lipid rafts
(Wysoczynski et al., 2005). A number of studies have suggested that lipid raft
localization is required for proper function of CXCR4 (Le et al., 2005; Nguyen et
al., 2005; Nguyen and Taub, 2002) and recently it has been shown that SDF
stimulation promotes the incorporation of Src tyrosine kinases, focal adhesion
kinase, PI3 kinase and the small G protein Rac into lipid rafts (Wysoczynski et
al., 2005). This agonist promoted clustering of receptor and effectors into lipid
rafts might be a way of ensuring that the proper signaling pathways are activated.
G Protein Signaling
Upon activation of CXCR4, a number of signaling pathways are activated
leading to a variety of biological responses (Figure 3) (Kucia et al., 2004). As
CXCR4 couples to the Gi family of proteins, the use of pertussis toxin (PTX),
which ADP-ribosylates Gα i and inhibits GPCR/Gi coupling, is a useful tool to
delineate pathways that are G protein-dependent and -independent. To date, the
majority of signaling pathways and biological outcomes of CXCR4 activation are
PTX-sensitive and therefore dependent on activation of Gi proteins. Activated Gi
is able to inhibit adenylyl cyclase as well as activate the Src family of tyrosine
kinases while liberated Gβγ recruites GRK2/3 to the plasma membrane and
activates PLC-β and phosphoinositide-3 kinase (PI3K) ultimately leading to the
regulation of processes such as gene transcription, cell migration, and cell
adhesion (Figure 3).
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Figure 3. Signal transduction pathways and regulation of CXCR4
SDF binding to CXCR4 leads to the activation of multiple G protein-dependent
signaling pathways, resulting in diverse biological outcomes such as migration,
adhesion, and transcriptional activation. Pathways activated and outcomes
elicited may differ between CXCR4 + cell types. Two potential G proteinindependent pathways have been described. Tyrosine phosphorylation of
CXCR4 results in the recruitment and activation of the JAK/STAT pathway, while
p38 and ERK activation has been shown to be partially dependent on arrestin3.
Following activation, GRK phosphorylation results in the recruitment of
arrestin2/3 and subsequent internalization. CXCR4 is also ubiquitinated by AIP4
at the plasma membrane, which results in its sorting to and degradation in
lysosomes. However, a portion of the internalized receptor may also recycle back
to the plasma membrane. Adapted from Busillo, J.M. and Benovic, J.L. (2007)
Regulation of CXCR4 signaling. Biochim Biophys Acta, 1768, 952-963.
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G Protein Independent Signaling
Activation of the JAK/STAT pathway by CXCR4 has been proposed to be
G protein independent (Vila-Coro et al., 1999). SDF induced the transient
association of JAK2 and JAK3 with CXCR4, leading to the activation and nuclear
translocation of a number of STAT proteins. While JAK/STAT activation was G
protein-independent, pretreatment with PTX led to a prolonged association of
JAK with CXCR4 suggesting that G protein coupling is involved in JAK/STATreceptor complex recycling (Vila-Coro et al., 1999).
The non-visual arrestins have classically been considered to shut off
signal transduction following receptor activation, a process termed
desensitization (Krupnick and Benovic, 1998). Indeed, lymphocytes isolated from
arrestin3 knock out mice display attenuated desensitization and enhanced G
protein coupling of CXCR4 (Fong et al., 2002b). However, these mice also
display a decreased chemotactic response to SDF, possibly due to the ability of
arrestin3 to promote signaling (Fong et al., 2002b). In addition to signal
termination, arrestins are able to act as scaffolds for a number of signaling
molecules (DeFea et al., 2000b; Luttrell et al., 1999). These interactions may
serve to propagate signaling or even create a platform to allow for activation of
the proper signaling cascade (Lefkowitz and Shenoy, 2005). Consistent with
these observations, it has been reported that arrestin2 and 3 enhance CXCR4mediated ERK activation (Cheng et al., 2000) and arrestin3 is involved in p38
activation and migration following SDF stimulation (Sun et al., 2002). Taken
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together, non-visual arrestins may play a role in regulating CXCR4/Gi interaction
as well as SDF-promoted signaling and cell migration.
Regulation of Signaling
As described earlier, three processes primarily regulate GPCRs:
desensitization (homologous and heterologous), internalization, and degradation.
The process of homologous desensitization, or becoming refractory to continued
stimulation, is initiated by GRK phosphorylation of serine/threonine residues of
the third intracellular loop or cytoplasmic tail (C-tail) following receptor activation
(Krupnick and Benovic, 1998). This phosphorylation allows for the subsequent
binding of arrestin2 and/or arrestin3, effectively uncoupling the receptor from
further G protein activation and often targeting the receptor for internalization
(Krupnick and Benovic, 1998).
Upon SDF activation, CXCR4 is rapidly phosphorylated and internalized
(Haribabu et al., 1997; Orsini et al., 1999; Signoret et al., 1997; Signoret et al.,
1998). Removing the 45 amino acid C-tail of CXCR4, which contains 15 serine
and 3 threonine residues, eliminates agonist-promoted phosphorylation
(Haribabu et al., 1997), enhances receptor activity, and attenuates receptor
internalization (Signoret et al., 1997).

Truncation and alanine scanning

mutagenesis has suggested multiple regions in the CXCR4 C-tail as potential
phospho-acceptor sites (Orsini et al., 1999; Signoret et al., 1998). Mutation of
Ser338 and Ser339 resulted in reduced SDF-promoted phosphorylation of
CXCR4 as did truncation of the C-terminal 7 amino acids, which removes serines
346, 347, 348, 351, and 352 (Orsini et al., 1999). Recently, a phospho-specific
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antibody directed against phospho-Ser339 also revealed increased
phosphorylation of Ser339 following SDF stimulation (Woerner et al., 2005).
Interestingly, increased phosphorylation of Ser339 was also observed following
EGF or phorbol ester treatment (Woerner et al., 2005), suggesting that this may
be a potential PKC phosphorylation site. To date, the GRKs responsible for
phosphorylation of CXCR4 have not been identified, although GRK2 (Cheng et
al., 2000; Orsini et al., 1999), GRK3 (Balabanian et al., 2008), and GRK6 (Fong
et al., 2002b; Vroon et al., 2004) have been implicated. Overexpression of GRK2
was able to enhance SDF-mediated internalization of CXCR4, which was further
increased by the co-expression of arrestin3 (Cheng et al., 2000; Orsini et al.,
1999). Interestingly, GRK2 has also been suggested to negatively regulate
CXCR4 signal transduction at a level downstream of the receptor, possibly via
interaction with MEK (Jimenez-Sainz et al., 2006). Overexpression of GRK3 was
shown to restore internalization of wild type, but not of a CXCR4 mutant lacking
the last 15 amino acids in fibroblast cells (Balabanian et al., 2008). Accordingly,
siRNA-mediated knock down of GRK3, but not GRK2, led to a reduction in
CXCR4 internalization. Furthermore, overexpression of GRK3 was able to
restore normal CXCR4-mediated G protein activation and migration in cells
isolated from patients diagnosed with WHIM syndrome despite expressing wild
type CXCR4 (Balabanian et al., 2008).

Lymphocytes and neutrophils isolated

from mice with a targeted disruption of GRK6 showed enhanced CXCR4 function
and a lack of desensitization (Fong et al., 2002b; Vroon et al., 2004), which was
not seen in cells isolated from mice lacking GRK5 (Fong et al., 2002b). These
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data suggest that there may be multiple kinases regulating CXCR4 in response
to SDF stimulation. As has recently been suggested for the angiotensin receptor
(Ahn et al., 2004; Kim et al., 2005), vasopressin receptor (Ren et al., 2005), and
β2AR (Shenoy et al., 2006; Violin et al., 2006), the coordinated action of these
kinases may be necessary for proper receptor regulation by dictating specific
interactions through alternative phosphorylation patterns.
Many GPCRs also undergo a process termed heterologous
desensitization, which is mediated by the activation of second messenger
dependent protein kinases such as PKA and PKC. Sequence analysis of CXCR4
shows that multiple serines in the C-tail are potential PKC phosphorylation sites.
Consistent with this, direct activation of PKC using phorbol esters results in
phosphorylation (Haribabu et al., 1997) and internalization (Orsini et al., 1999;
Signoret et al., 1997; Signoret et al., 1998) of CXCR4. Although the sites of
phorbol ester induced phosphorylation of CXCR4 have not been completely
determined, a significant decrease in phorbol ester induced internalization was
observed when either Ser324 and Ser325 or Ser338 and Ser339 were mutated
(Signoret et al., 1998) while phorbol ester treatment induced phosphorylation of
Ser339 (Woerner et al., 2005). More physiologically relevant stimuli that lead to
PKC activation such as T or B cell receptor engagement (Guinamard et al., 1999;
Peacock and Jirik, 1999), formyl peptide receptor activation (Li et al., 2001;
Selleri et al., 2005), CXCR1 activation (Richardson et al., 2003), CXCR2
activation (Suratt et al., 2004), or CCR5 activation (Hecht et al., 2003) are also
able to induce CXCR4 internalization. Interestingly, T cells overexpressing the
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HIV-1 protein Tat, had enhanced SDF-mediated internalization of CXCR4 that
was attributed to activation of the atypical PKC, PKCζ (Hidalgo-Estevez et al.,
2008). The functional significance of this is currently unknown, though it may
affect homing of memory T cells, which have been shown to express CXCR4
(Nanki et al., 2000).
Phosphorylation of tyrosine residues in CXCR4 has also been observed
following both SDF (Vila-Coro et al., 1999) and cytokine activation (Wang et al.,
2001), although the residues that are phosphorylated are currently unknown.
SDF-promoted tyrosine phosphorylation may promote the activation of the
JAK/STAT pathway (Vila-Coro et al., 1999; Zhang et al., 2001), while cytokineinduced tyrosine phosphorylation may be a way of promoting ligand-independent
internalization of CXCR4 (Wang et al., 2001).
Internalization and Degradation
As outlined above, the non-visual arrestins also act as adaptor proteins
and, through their interaction with clathrin and AP-2, target GPCRs to CCPs for
internalization (Moore et al., 2007). CXCR4 is thought to internalize in an
arrestin- and clathrin-dependent manner (Cheng et al., 2000; Marchese et al.,
2003b; Orsini et al., 1999). Moreover, mutation of potential phospho-acceptor
sites has identified regions important for constitutive (Futahashi et al., 2007) and
heterologous or homologous internalization of CXCR4 (Orsini et al., 1999;
Signoret et al., 1998) (Figure 4).
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Figure 4. Amino acid sequence of the C terminal tail of CXCR4
The C terminal tail of CXCR4 contains 15 serine and 3 threonine residues.
Truncation and alanine scanning mutagenesis has identified multiple residues as
potential phospho-acceptor sites (highlighted in yellow) as well as those residues
important for degradation (highlighted in red). Evidence to date suggests that
multiple GRKs are responsible for homologous desensitization of CXCR4.
Additionally, multiple residues are potential PKC phosphorylation sites.
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Upon internalization, GPCRs can be recycled back to the plasma membrane or
sorted to the lysosome for degradation (Marchese et al., 2003a). CXCR4 can
recycle back to the plasma membrane following PKC-mediated internalization
(Signoret et al., 1997), however, the receptor recycles poorly following SDF
stimulation (Tarasova et al., 1998). In fact, CXCR4 has been shown to be
ubiquitinated, sorted to the lysosome, and degraded (Marchese and Benovic,
2001), a process mediated by the E3 ubiquitin ligase AIP4 (Marchese et al.,
2003b). Based on electrophoretic mobility shift, the receptor is most likely monoubiquitinated on one of three lysines residues (Lys327, Lys331, or Lys333) in the
C-tail. Mutation of these three residues to arginine eliminates ubiquitination and
degradation of the receptor (Marchese and Benovic, 2001). Interestingly,
mutation of Ser330 to alanine partially inhibited degradation of CXCR4 without
affecting receptor internalization while mutation of Ser324 and Ser325 partially
inhibited SDF-promoted internalization but completely disrupted degradation
(Marchese and Benovic, 2001). Ubiquitination of CXCR4 occurs at the cell
surface and the rate limiting step for degradation appears to be sorting to the
lysosome for degradation (Marchese et al., 2003b).

Interestingly, recent

evidence has shown that arrestin2 mediates sorting of CXCR4 into the
degradative pathway (Bhandari et al., 2007). Taken together, these data suggest
that phosphorylation of specific residues may dictate the fate of the receptor
following internalization.
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CXCR4 DYSREGULATION IN DISEASE
WHIM Syndrome
Heterozygous mutations in the gene encoding CXCR4 leads to a rare
combined immunodeficiency characterized by warts, hypogammaglobulinemia,
recurrent bacterial infection, and myelokathexis, known as WHIM syndrome
(Diaz and Gulino, 2005; Gulino, 2003). WHIM syndrome is currently the only
immunological disease associated with mutations to a chemokine receptor (Diaz
and Gulino, 2005). The mutations identified to date (one frameshift and three
nonsense mutations) all truncate the C-terminal tail of CXCR4 (Figure 5)
eliminating 10 to 19 of the distal tail amino acids, including a number of potential
phosphorylation sites (Gulino et al., 2004; Hernandez et al., 2003). This leads to
the expression of a receptor with altered regulation. Following activation, there is
a lack of desensitization (Balabanian et al., 2005; Gulino et al., 2004), enhanced
chemotaxis (Gulino et al., 2004; Kawai et al., 2005), an increase in F- actin
polymerization (Balabanian et al., 2005), enhanced calcium mobilization (Kawai
et al., 2005), and a decrease in SDF promoted internalization (Balabanian et al.,
2005; Kawai et al., 2005), although one report found no difference in calcium
mobilization or internalization (Gulino et al., 2004).
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Figure 5. Amino acid sequence of the C terminal tail of CXCR4 and known
WHIM syndrome mutations
Amino acid sequence of CXCR4 as a result of the various germline mutations
identified to date resulting in WHIM syndrome. These C terminal truncations
result in expression of a receptor with altered regulation. In addition to these
identified mutations, two patients have been identified with WHIM syndrome
despite expressing wild type CXCR4, suggesting the loss of a downstream
regulatory protein.
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Interestingly, WHIM syndrome has been reported in two patients
expressing a wild type CXCR4 (Balabanian et al., 2005). Functional assays
using cells isolated from these patients revealed that, consistent with classical
WHIM cases, there was a lack of desensitization and internalization of CXCR4
following SDF stimulation. The lack of germline mutations in these receptors
suggests that there is a change in some downstream regulator such as a GRK or
arrestin. Indeed, it has recently been shown that GRK3 levels are specifically
decreased in one of the two patients (Balabanian et al., 2008) and re-expression
of GRK3 was able to rescue receptor internalization and normalize actin
polymerization and cell migration. It is interesting to note that mice lacking either
GRK6 (Fong et al., 2002b; Vroon et al., 2004) or arrestin3 (Fong et al., 2002b)
also have enhanced receptor function in response to SDF stimulation, similar to
those seen in WHIM syndrome, suggesting that tissue specific differences in
protein expression or activity possibly differentially regulates CXCR4 activity.
Cancer
The expression of CXCR4 has been detected in 23 different cancers of
various origins (Balkwill, 2004b) and is the most common chemokine receptor
expressed on cancer cells (Zlotnik, 2006a). The expression of CXCR4 on
hematopoetic malignancies is not surprising given the critical role of the receptor
in development of these cells (Ara et al., 2003; Egawa et al., 2001; Lapidot and
Kollet, 2002; Tachibana et al., 1998; Zou et al., 1998). However, in a variety of
other cancers, CXCR4 expression is enhanced compared to the adjacent normal
tissue, which may have little or no CXCR4 (Muller et al., 2001; Scotton et al.,
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2001; Sun et al., 2003). A potential underlying mechanism for this may result
from changes that occur within the vasculature or O2 carrying capacity of cells
leading to hypoxic conditions during tumor progression (Hirota and Semenza,
2006). Hypoxia induces the activation of hypoxia inducible factor 1 (HIF-1) which
in turn promotes expression of a number of target genes (Hirota and Semenza,
2006) including CXCR4 (Schioppa et al., 2003; Staller et al., 2003; Zagzag et al.,
2005). Further evidence regarding the role of HIF-1 came from studies of the
tumor suppressor von Hipple Lindau (VHL). Inactivating mutations of VHL, which
normally targets HIF-1 for degradation, account for the increased CXCR4
expression in renal cell carcinomas (Schioppa et al., 2003; Staller et al., 2003;
Zagzag et al., 2005).
A number of other factors also have the ability to enhance CXCR4
expression specifically during cancer progression.

For example, vascular

endothelial growth factor (VEGF) (Bachelder et al., 2002) or activation of nuclear
factor kappa B (NF-κB) (Helbig et al., 2003) enhances CXCR4 expression in
breast cancer promoting invasion and metastasis, respectively. Additionally, it
has been shown that CXCR4 expression can be induced by the oncoproteins
PAX3-FKHR (Libura et al., 2002; Tomescu et al., 2004) and RET/PTC
(Castellone et al., 2004). CXCR4 expression as a result of the PAX3-FKHR
fusion leads to enhanced migration and adhesion of rhabdomyosarcoma cells
(Libura et al., 2002), while RET/PTC induced expression enhanced the
transforming ability of breast cancer cells (Castellone et al., 2004). Furthermore,
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altering the activity of (Lee et al., 2005) or deletion of (de Nigris et al., 2008) YY1
results in decreased or enhanced CXCR4-mediated metastases, respectively.
Increased cell surface expression of CXCR4 may also be the result of
altered regulation, independent of effects on transcription/translation.
Ubiquitination of CXCR4 is a modification regulating the expression of CXCR4
post-translationally (Marchese and Benovic, 2001; Marchese et al., 2003b). It has
been found that HER2/neu positive cancer cells have increased expression of
CXCR4 as a result of inhibition of receptor ubiquitination (Li et al., 2004).
Expression of AIP4, the E3 ubiquitin ligase responsible for ubiquitination of
CXCR4 (Marchese et al., 2003b), was able to reverse this effect (Li et al., 2004).
Moreover, the recent finding that cytokine-independent survival kinase (CISK)
associates with and inhibits AIP4 function (Slagsvold et al., 2006) provides a
potential link between HER2 positive cancers and the attenuated degradation of
CXCR4 (Li et al., 2004). It will be interesting to examine if altered CXCR4
ubiquitination is a global phenomenon in CXCR4-overexpressing cancers or if
this effect is specific to HER2/neu expressing cancers.
It is expected that the functional consequence of CXCR4 expression on
cancer cells would be varied based on the numerous roles of the CXCR4-SDF
signaling axis. For example, the combination of CXCR4 expression and
interaction with stromal or nurse-like cells in chronic lymphocytic leukemia
(Burger et al., 2000) and multiple myeloma (Damiano et al., 1999) may account
for resistance to spontaneous/drug induced apoptosis and cell adhesionmediated drug resistance, essentially providing a protective niche. Tumor

45

progression is also affected by CXCR4-SDF-1 signaling through the induction of
tumor-associated integrin activation and signaling (Hartmann et al., 2005).
Finally, in addition to mediating metastases (see below), CXCR4-SDF-1 signaling
may affect the survival of the tumor at the metastatic site. Enhanced CXCR4
signaling has been shown to down-regulate phosphoglycerate kinase (PGK), a
key regulator of angiogenesis, activating angiogenic pathways and promoting
tumor survival (Wang et al., 2007).
Since SDF is a chemokine, an attractive hypothesis is that CXCR4
expression correlates with metastasis. Consistent with this, activation of CXCR4
stimulates the production of matrix metalloproteases (Fernandis et al., 2004;
Janowska-Wieczorek et al., 2000; Samara et al., 2004; Spiegel et al., 2004)
potentially facilitating the ability of cancers to egress from the primary tumor site.
Furthermore, SDF signaling is also able to enhance integrin activity (Campbell et
al., 1998; Glodek et al., 2003; Wright et al., 2002) enhancing cell adhesion under
flow conditions. Upon entering the blood or lymphatic systems, if CXCR4 truly
mediates metastasis, tumors would preferentially migrate and adhere to areas
that highly express SDF-1.

Breast cancer follows this distinct pattern of

metastasis, namely to lymph nodes, lung, liver, and bone marrow all of which
highly express SDF-1 (Allinen et al., 2004; Muller et al., 2001). Accordingly,
neutralizing antibodies to CXCR4 (Muller et al., 2001) or siRNA knock down
(Lapteva et al., 2005; Liang et al., 2005) inhibit metastasis and growth of breast
cancer cells.

Other cancers, such as small cell lung cancer, thyroid,

neuroblastoma, hematological and hepatic malignancies also metastasize to
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areas with high SDF-1 expression (Burger et al., 2003; Geminder et al., 2001;
Hwang et al., 2003; Kijima et al., 2002; Schimanski et al., 2006). In spite of this
evidence, studies attempting to correlate expression with metastatic potential
have yielded mixed results.

Whereas CXCR4 expression increased with

aggressiveness of prostate tumors (Sun et al., 2003) there was not a significant
correlation of CXCR4 expression and distant breast cancer cell metastasis (Kato
et al., 2003), although the extent of nodal metastasis was greater in cells
expressing high levels of CXCR4 compared to those with lower levels (Kato et
al., 2003).

Recently, CXCR4 expression on hepatocellular carcinoma was

suggested to correlate with local tumor progression, lymphatic and distant
metastasis, as well as negatively impact the 3-year survival rate of these patients
(Schimanski et al., 2006).
On the other hand, cancers such as lymphomas, glioma, ovarian, and
pancreatic have a high expression of SDF-1 at the primary site (Corcione et al.,
2000; Koshiba et al., 2000; Scotton et al., 2002; Zhou et al., 2002). Additionally,
colonic epithelia normally express CXCR4 (Jordan et al., 1999). Thus, the
CXCR4-SDF-1 interaction could be retaining tumor cells that originate at these
sites, analogous to the retention of B-cells and neutrophils in the bone marrow
during development. Epigenetic mechanisms that negatively regulate the
expression of SDF or CXCR4 may be necessary in order for metastasis to occur.
One example is DNA methylation, a modification typically associated with
inactivation of tumor suppressors (Jones and Baylin, 2002). It has recently been
shown that methylation of the SDF promoter in colonic epithelium promotes
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metastasis of these tumors (Wendt et al., 2006). The CXCR4 promoter is also
methylated in a number of pancreatic cancers, decreasing mRNA and protein
levels (Sato et al., 2005). Though not addressed in the study, this may be a
mechanism that allows pancreatic cancers to metastasize from these sites.
As detailed above, the C-tail is absolutely critical for proper regulation of
CXCR4. Interestingly, expression of a C-tail truncated mutant of CXCR4 in MCF7 mammary carcinoma cells led to an epithelial-to-mesenchymal transition (Ueda
et al., 2006). Oligomicroarray analysis showed that there was a down regulation
of E-cadherin and Zonula occludens, thereby disrupting cell-to-cell contacts, with
a concomitant increase in ERK activation.

There was also an increased

expression of a number of growth factor receptors. While there have been no
cancers described as a result of truncation of CXCR4, this may give insight into
the signaling pathways critical for cancer progression and metastasis.
Recent evidence also suggests that, in some breast cancers, receptor
expression and functional activity are not linked (Holland et al., 2006). Examining
a variety of breast cancer cell lines, ranging from untransformed but immortalized
to highly invasive, it was concluded that receptor expression alone does not lead
to the acquisition of an invasive phenotype. Specifically, it was speculated that
there were alterations in G protein coupling to the receptor. Untransformed or
transformed non-invasive cells were not able to properly couple to Gi, and
therefore, were not able to elicit Ca2+ mobilization, ERK activation or migration;
signaling pathways conserved in the invasive lines. Interestingly, as B cells
develop into mature cells, they progressively lose the ability to respond to SDF-1
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even though surface expression of CXCR4 remains relatively high (Fedyk et al.,
1999; Honczarenko et al., 1999). However, as they further differentiate into
plasma cells, they regain responsiveness to SDF (Hargreaves et al., 2001). The
underlying mechanisms regulating this phenomenon in B cells are currently not
known, though similar mechanisms may be occurring as a result of the transition
to a more malignant phenotype in these breast cancer cells.
OBJECTIVES
An emerging theme in GPCR regulation is the possibility of differential
regulation dictated by the phosphorylation pattern, or “barcode”, elicited by the
different members of the GRK family. Given the multifaceted role CXCR4 plays in
diverse processes from development to cancer metastasis, CXCR4 is a very
intriguing therapeutic target. An ample body of work has been generated in
delineating potential pathways that mediate specific effects (e.g., leading to
metastasis), however, a detailed basic understanding of receptor regulation is
lacking. Understanding the precise mechanisms regulating CXCR4 function at
the receptor level should provide insight into attractive therapeutic targets in this
pathway. Furthermore, this will allow for translational research opportunities to
dissect the specifics of how receptor regulation is altered in disease.
Our objectives were to 1) establish a model system in which to
characterize the regulation of GPCRs, 2) use this model system to identify
agonist-promoted sites of phosphorylation of CXCR4, 3) identify the kinases that
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mediate site-specific phosphorylation, and 4) characterize the functional role of
site-specific phosphorylation.
Classically, the β2AR and rhodopsin have served as elegant models for
establishing the current paradigms of GPCR signaling and regulation. However,
accumulating evidence suggests that the molecular mechanisms that underlie
receptor regulation are extremely diverse and receptors need to be studied
individually. Therefore, we chose to establish a cellular system that would allow
us to systematically analyze the proteins involved in receptor regulation as well
as biochemically characterize receptor phosphorylation. Human Embryonic
Kidney 293 (HEK293) cells are an excellent model system as they express a
number of GPCRs (including CXCR4), GRK2, 3, 5, 6, the non-visual arrestins,
and multiple PKC isoforms endogenously. In order to validate HEK293 cells as a
model system, our aims included 1) screening HEK293 cells for a candidate
receptor endogenously expressed, 2) identify downstream signaling pathways
that can be used to characterize receptor regulation, and 3) systematically
analyze proteins known to be involved in regulating the candidate receptor using
small molecule inhibitors and small interfering RNA.
CXCR4 is primarily phosphorylated on multiple residues of the C terminal
tail, which contains 15 serine and 3 threonine residues (Haribabu et al., 1997;
Orsini et al., 1999). To date, GRK2 (Orsini et al., 1999; Cheng et al., 2000),
GRK3 (Balabanian et al., 2008), GRK6 (Fong et al., 2004; Vroon et al., 2004),
and PKC (Signoret et al., 1997; Orsini et al., 1999) have been implicated in
regulating CXCR4, though the specific sites of phosphorylation, kinase
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specificity, and functional role of site-specific phosphorylation are unknown.
Therefore, to identify agonist promoted sites of phosphorylation and what
kinase(s) are involved, our aims included 1) establish a HEK293 cell line that
stably expressed Flag tagged CXCR4 at moderate levels, 2) affinity purify
CXCR4 and use tandem mass spectrometry to identify SDF-1-promoted sites of
phosphorylation, 3) develop phospho-specific antibodies against the identified
sites, and 4) use a combination of small molecule inhibitors and siRNA to define
kinase-specific sites of phosphorylation.
Accumulating evidence suggests that site- and tissue-specific
phosphorylation of GPCRs has distinct effects on both receptor regulation and
signaling (Tobin et al., 2008). Targeted deletion of GRK6 in mice results in
enhanced receptor function following SDF-1 stimulation. However, neutrophils
have enhanced while T cells are deficient in SDF-1-mediated chemotaxis.
Interestingly, T cells isolated from mice specifically lacking arrestin3 display a
similar phenotype as those from GRK6 mice. Furthermore, arrestin3 has been
shown to enhance SDF-1-mediated chemotaxis and activation of MAPK signaling
pathways (Cheng et al., 2000; Sun et al., 2002). Therefore, our final aims were
to 1) characterize the roles of the GRKs and non-visual arrestins in regulating
signal transduction of endogenous CXCR4 in HEK293 cells, and 2) ensure that
stable over-expression of CXCR4 does not alter this regulation.
We were able to establish a model system by studying the regulation of
the M3 muscarinic acetylcholine receptor (M3 mAChR), a Gq-coupled receptor.
Consistent with what is currently known, we have shown that GRK2, GRK3,
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casein kinase 1α, and the non-visual arrestins negatively regulate receptor
activity (Budd et al., 2000; Wu et al., 2000; Willets et al. 2001; Willets et al., 2002;
Willets et al., 2003), as demonstrated by changes in calcium mobilization and
ERK activation. Furthermore, we were also able to show that GRK2 regulated
calcium mobilization and ERK activation through interactions with Gq. Finally,
we were also able to validate the combination of small molecule inhibitors and
siRNA-mediated silencing as a method to unravel and better understand the
complex regulatory mechanisms in place for any given GPCR.
Using this model system, we were then able to identify sites of
phosphorylation by optimizing an affinity based purification strategy for CXCR4
from HEK293 cells.

Following stimulation and purification, CXCR4 was

subjected to proteolytic digestion and tandem mass spectrometry to identify
agonist-promoted sites of phosphorylation. Using the mass spectrometry data
and previous studies (Marchese et al., 2001), phospho-specific antibodies were
successfully generated against phospho-Ser324/325 (pS324/5) and pS330.
Furthermore, we also used a previously characterized antibody that is specific for
pSer339 (Woerner et al., 2005). Using these antibodies, we were then able to
characterize both the kinetics and kinase specificity at these residues. We
provide novel evidence for a role of PKC in phosphorylating Ser324/5 following
SDF stimulation. Additionally, we show that GRK6 phosphorylates multiple
residues with distinct kinetics.
Analyzing calcium mobilization and ERK1/2 activation following systematic
knocking down of GRK2, 3, 5, and 6, arrestin2, and arrestin3 has given
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substantial insight into the functional role of site-specific phosphorylation.
Importantly, we show that the endogenous and overexpressed receptors are
regulated in a similar manner. Furthermore, we demonstrate that the GRKs and
arrestins differentially regulate signaling. Together, this data suggests that
CXCR4 function and signaling are dynamically regulated by phosphorylation and
subsequent protein/protein interactions. Moreover, we have developed tools to
allow for a complete analysis of CXCR4 function in a variety of tissues and
disease states.
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INTRODUCTION
Activation of G protein-coupled receptors (GPCRs) by agonist occupancy
leads to a conformational change in the receptor that promotes the activation of
heterotrimeric G proteins, which in turn activate a variety of effectors leading to
downstream signaling events (Pierce et al., 2002).

Activated GPCRs are

regulated by three principal mechanisms: desensitization, internalization, and
down-regulation. Receptor desensitization is initiated by the phosphorylation of
serine/threonine residues by GPCR kinases (GRKs) which promotes the high
affinity binding of arrestins, uncoupling the receptor from G protein and
terminating signaling (Krupnick and Benovic, 1998).
There are seven members of the GRK family that are grouped into three
subfamilies based on sequence and functional similarity: GRK1 and GRK7;
GRK2 and GRK3; and GRK4, GRK5, and GRK6. GRK2, GRK3, GRK5, and
GRK6 are ubiquitously expressed, while GRK1, GRK4, and GRK7 have a
restricted expression pattern. Much of the research determining specific GPCRGRK interaction has relied on techniques such as heterologous overexpression,
dominant-negative constructs, and more recently RNA interference (Krupnick
and Benovic, 1998; Iwata et al., 2005; Kim et al., 2005).
The non-visual arrestins, arrestin2 (β-arrestin1) and arrestin3 (β-arrestin2)
bind to activated, phosphorylated GPCRs subsequently terminating G protein
activation and targeting the receptors to clathrin coated pits for internalization
(Moore et al., 2007). Arrestins have also been shown to act as scaffolding
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proteins to promote downstream signaling events, such as activation of mitogenactivated protein kinases (Lefkowitz and Shenoy, 2005).
The muscarinic acetylcholine receptors (mAchRs) represent a subfamily of
GPCRs with five subtypes, M1 – M5. The M3 mAchR couples to Gq resulting in
phospholipase C-β (PLC-β) activation, and production of inositol trisphosphate
(IP3) and diacylglycerol (DAG), which leads to calcium release from intracellular
stores and protein kinase C (PKC) activation. Additionally, the M3 mAchR can
activate extracellular signal-regulated kinase (ERK), although the mechanism by
which this occurs is unclear.

Upon activation, the M3 mAchR is rapidly

phosphorylated on serine/threonine residues within the third intracellular loop
(Tobin et al., 1997) and C terminal tail (Budd et al., 2000), although it is unclear
which kinases mediate receptor phosphorylation and regulation. Wu et al.
showed that GRK2 phosphorylates the M3 mAchR in a Gβγ dependent manner
and mapped the phosphorylation sites to

331

SSS333 and

348

SASS351 in the third

intracellular loop (Wu et al., 2000). GRK3 also has the ability to phosphorylate
the receptor but receptor regulation by GRK3 appears to occur primarily through
modulation of PLC-β activity (Willets et al., 2001; Willets et al., 2002; Willets et
al., 2003). Willets and coworkers also showed that GRK6 regulates the M3
mAchR by phosphorylation while GRK2 and GRK5 were found to have no effect
(Willets et al., 2001; Willets et al., 2002; Willets et al., 2003). In addition to GRKmediated phosphorylation, casein kinase 1a (CK1α) has also been shown to
phosphorylate the M3 mAchR in an agonist dependent manner although this
alone was insufficient to mediate receptor desensitization (Budd et al., 2000).
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Finally, arrestins do not appear to be required for M3 mAchR internalization (Lee
et al., 1998; Mundell and Benovic, 2000), but are involved in receptor
desensitization with no discernable specificity between arrestin2 and arrestin3
(Mundell and Benovic, 2000).
One major unanswered question regarding the physiological regulation of
GPCRs is to understand which GRKs and arrestins regulate a given receptor
subtype. To date, a limited number of GRKs and arrestins have been identified,
whereas more than 700 mammalian GPCRs have been cloned (Gainetdinov et
al., 2004). Studies over the past decade have defined the ability of individual
GRKs, second messenger dependent kinases (e.g., PKA or PKC), and arrestins
to regulate GPCRs in model systems. However, the mechanisms by which
GRKs target endogenous GPCRs are still unknown. Using either wild type
GRK2, kinase dead GRK2, or mutants deficient in Gaq binding, we previously
showed that the human H1 histamine receptor was specifically regulated by
GRK2 mainly through regulation of activated Gq (Iwata et al., 2005). In this
report, we used RNA interference to target proteins specifically involved in the
agonist dependent regulation of the endogenous M3 mAchR in HEK293 cells. We
found that there was differential GRK-mediated regulation of this receptor as
assessed by calcium signaling and ERK activation. In addition, knockdown of
either arrestin2 or arrestin3 resulted in enhanced signaling from the receptor,
with different temporal effects. Furthermore, we show that, in addition to GRKs,
CK1α has a negative role in M3 mAchR mediated calcium mobilization. Taken
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together, our results show that multiple proteins mediate agonist-dependent
regulation of M3 mAchR signaling.

EXPERIMENTAL PROCEDURES
Materials
HEK293 cells were from Microbix Biosystems, Inc (Toronto, Canada)
while carbachol was from EMD Biosciences (San Diego, CA). Pirenzepine and
p-fluorohexahydro-sila-difenol (pFHHsiD) were from Sigma-Aldrich (St. Louis,
MO) and Lipofectamine 2000 and Opti-MEM® were from Invitrogen (Carlsbad,
CA). Phospho-specific p44/p42 polyclonal antibody was from Cell Signaling
Technologies (Beverly, MA). Polyclonal ERK2, CK1a and GRK3 antibodies were
from Santa Cruz (Santa Cruz, CA). Anti-β-arrestin monoclonal antibody was
from BD Biosciences Pharmagen (San Diego, CA). Anti-GRK4-6 monoclonal
antibody was from Upstate Cell Signaling Solutions (Waltham, MA) while the
GRK2 monoclonal antibody was produced in our laboratory and anti-a-tubulin
monoclonal antibody was from Sigma (St. Louis, MO).
Synthesis of small interfering RNAs (siRNAs)
All siRNAs were chemically synthesized by Dharmacon, Inc (Chicago, IL).
The GRK2, GRK5 and CK-1a siRNAs were reported previously (Iwata et al.,
2005; Kim et al., 2005; Liu et al., 2002). The GRK3 siRNA sequence was 5´GCAGAAGUCGACAAAUUUA-3′ while 5´-GCGCUUGGCCUACGCCUAU-3´ was
used for GRK6. Arrestin2 and 3 siRNAs were purchased as a SMARTpool®.
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Non-specific control siRNA VIII (5´-AAACUCUAUCUGCACGCUGAC-3´) was
used as the control for all siRNA experiments.
Cell Culture and siRNA transfection
HEK293 cells were maintained in Dulbecco’s modified Eagles Media
supplemented with 10% FBS, 25 mM HEPES, pH 7.2, and 0.1 mM non-essential
amino acids in a 5% CO2 incubator at 37˚C. For transfection of GRK and casein
kinase siRNAs, HEK293 cells grown to 85 to 90% confluence in 100-mm dishes
were transfected with 600 pmol of siRNA using Lipofectamine 2000 in Opti-MEM.
After 6 hr, cells were split 1:2 and a second transfection of 600 pmol was
performed 24 hr after the initial transfection. Forty-eight hr after the second
transfection, cells were split for assay the following day.

For arrestin

SMARTpool® siRNAs, cells ~70% confluent were transfected with 600 pmol of
siRNA corresponding to either arrestin2 or arrestin3. Forty-eight hr later, cells
were split for assay the following day. Control siRNA was transfected in a similar
fashion as described above for each transfection condition.
Immunoblotting
To analyze siRNA target proteins, siRNA transfected HEK293 cells in a 6well plate were washed twice with ice cold PBS and lysed with buffer (20 mM
HEPES, pH 7.5, 10 mM EDTA, 150 mM NaCl, 1% Triton X-100 and one tablet of
Complete Inhibitor (Roche) per 50 ml) at 4°C on a rocker for 30 min. The lysates
were centrifuged at 4°C at 30,000 rpm in a TLA45 rotor for 30 min. The
supernatants were electrophoresed on a 10% SDS polyacrylamide gel,
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transferred to nitrocellulose, and immunoblotted using monoclonal anti-GRK2
(1:1000), polyclonal anti-GRK3 (1:200), monoclonal anti-GRK4-6 (1:3000),
monoclonal anti-β-arrestin-1 (1:1000) or polyclonal anti-CK1a (1:200), HRPlabeled secondary antibodies, and chemiluminescence. The blots were stripped
and reprobed using an anti-tubulin (1:7500) monoclonal antibody.

Measurement of intracellular calcium mobilization
Calcium mobilization was performed as previously described with slight
modifications (Iwata et al., 2005). In brief, HEK293 cells transfected with siRNAs
were harvested with Cellstripper (Mediatech, Herndon, VA), washed twice with
phosphate-buffered saline, and resuspended at 5 x 106 cells/ml in Hanks'
balanced salt solution (140 mM NaCl, 5 mM KCl, 10 mM HEPES, pH 7.4, 1 mM
CaCl2, 1 mM MgCl2, 1 mg/ml glucose) (Invitrogen) containing 0.025% bovine
serum albumin. The cells were then loaded with 3 µM Fura-2 acetoxymethyl
ester derivative (Fura-2/AM) (Molecular Probes, Eugene, OR) for 30 min at 37°C.
The cells were washed once in Hanks' solution, resuspended in Hanks' solution
containing 0.025% bovine serum albumin, incubated at room temperature for 15
min, washed twice in Hanks' solution, and then resuspended in Hanks' at a
concentration of 3 x 107 cells/ml. A typical experiment contained 1.5 x 106
cells/1.6 ml in a quartz cuvette and stimulation with different concentrations of
carbachol. Calcium mobilization was measured using excitation at 340 and 380
nm and emission at 510 nm in a fluorescence spectrometer (LS55, Perkin-Elmer
Life Sciences). Calibration was performed using 0.1% Triton X-100 for total
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fluorophore release and 15 mM EGTA to chelate free calcium. When antagonists
were used, cells were preincubated with the indicated antagonist for 30 seconds
prior to starting the fluorescent spectrometer and an additional 30 seconds prior
to stimulation with carbachol. Intracellular calcium concentrations were
calculated using a fluorescence spectrometer measurement program.

ERK activation assays
HEK293 cells, ~90% confluent in 6-well plates, were serum starved for at
least 6 hr. Following serum starvation, cells were stimulated with 100 µM
carbachol as indicated and washed once with ice cold PBS. Lysis buffer (1%
Triton X-100, 20 mM HEPES, pH 7.2, 150 mM NaCl, 10 mM EDTA, 1 µM sodium
orthovanadate, 3 mM sodium pyrophosphate, 10 mM sodium fluoride, and 1
Complete Inhibitor tablet per 50 ml) was added and plates were stored at –80˚C
until harvesting. Cells were thawed and scraped into lysis buffer on ice, vortexed
briefly, and debris was cleared by centrifugation at 14,000 rpm for 15 min. Equal
amounts of whole cell lysate were separated by electrophoresis on a 10% SDS
polyacrylamide gel, transferred to nitrocellulose, and proteins detected by
immunoblotting.

Nitrocellulose membranes were blocked for 1 hr at room

temperature in a 1:3 dilution of ODYSSEY® blocking buffer (LI-Cor® Biosciences).
A mixture of primary antibodies directed at ERK2 (monoclonal, Santa Cruz) and
phospho-ERK1/2 (polyclonal, Cell Signaling Technologies) in 100% ODYSSEY®
blocking buffer were incubated overnight at 4˚C. Nitrocellulose membranes were
washed with Tris Buffered Saline containing 0.1% Tween-20 (TBS-T) over 40
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min. The membranes were then incubated for 1 hr at room temperature with a
mixture of goat anti-rabbit Alexa® Fluorophore 680 conjugated (Molecular
Probes)

and

goat

anti-mouse

IRDye

800

conjugated

(Rockland

Immunochemicals) antibodies. Following a 1 hr incubation, the membranes were
washed with TBS-T for 60 min. Fluorescence was detected simultaneously using
the ODYSSEY® infrared imaging system (LI-Cor® Biosciences). When
antagonists were used, cells were incubated at 37°C with the indicated
antagonist for 5 minutes prior to stimulation with carbachol. Fluorescence
intensity of phosphorylated ERK2 was normalized to total ERK2 fluorescence,
and data are represented as fold-increase over basal (+/- SEM).
Statistical Analysis
Results were analyzed using a paired, two-tailed, students T-Test with
significance at p≤0.05.
RESULTS

Pharmacological characterization of the muscarinic acetylcholine receptor
subtype endogenously expressed in HEK293 cells
Using RNAi, we have previously shown that GRK2 regulates the
endogenously expressed H1 histamine receptor in HEK293 cells (Iwata et al.,
2005). We wanted to expand this approach to determine the regulation of other
endogenous GPCRs. Previous work has shown that HEK293 cells respond to
stimulation with carbachol, a non-specific mAchR agonist, with robust IP3
production and calcium mobilization that had been attributed to the M1 mAchR
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subtype (Mundell and Benovic, 2000). However, a recent microarray analysis of
commonly used cell lines suggested that the mAchR endogenously expressed in
these cells is the M3 receptor subtype (Hakak et al., 2003). In light of this, we
sought to pharmacologically determine which mAchR subtype is actually
expressed in HEK293 cells. Cells loaded with the ratiometric calcium indicator
Fura-2/AM display a robust increase in calcium mobilization in response to
carbachol stimulation (Figure 6A) with an EC50 of 20 µM (data not shown).
Incubation with the antagonist p-FHHsiD, which has some selectivity for the M3
(pKi = 7.1) (de la Vega et al., 1997) completely inhibited calcium mobilization in
response to carbachol while the selective M1 mAchR antagonist pirenzepine,
only slightly inhibited calcium mobilization (Figure 6A). This result is in line with
previous reports demonstrating that pirenzepine selectively inhibits the M1
mAchR (pKi 8.0), but at higher concentrations is able to inhibit the M3 subtype
(pKi 6.7) (de la Vega et al., 1997). In addition, there was no calcium response
when the cells were stimulated with the M1/M4 mAChR-selective agonist McN-A343 (data not shown).
To further investigate the subtype of mAchR expressed, we also analyzed
the effects of the M1 and M3 selective antagonists on carbachol-stimulated ERK
activation. GPCRs activate ERK1/2 via a number of pathways (Werry et al.,
2005) and both the M1 and M3 mAchRs have been shown to activate ERK1/2 in a
number of cell types (Budd et al., 1999; Guo et al., 2001). Carbachol-mediated
ERK activation in HEK293 cells is dose dependent (EC50 ~8 µM), peaking at 5
min and returned to basal levels by 60 min (Figure 6B, top panel). The addition of
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p-FHHsiD completely blocked ERK1/2 activation in response to carbachol,
whereas pirenzepine had no effect (Figure 6B). These results confirm that the
primary mAchR subtype in HEK293 cells is the M3.
We also wanted to determine whether PKC was responsible for ERK
activation following M3 mAchR stimulation. Previous evidence suggests that the
novel PKC isoforms are responsible for M3 mAchR-mediated ERK activation,
including PKCε in SK-N-BE2(C) cells (Kim et al., 1999) and a calcium
independent PKC in Chinese hamster ovary cells (Wylie et al., 1999).
Furthermore, it has been shown recently that the M3 mAchR was shown to
regulate the Kir 3.1/3.2 potassium channel through activation of PKC-δ in
HEK293 cells (Brown et al., 2005). To establish whether PKC-δ is involved in M3
mAchR-mediated ERK activation, we used bisindolylmaleimide I (Bis I), a general
PKC inhibitor, and rottlerin, which selectively inhibits PKC-δ (Gschwendt et al.,
1994). Rottlerin significantly inhibited carbachol-mediated ERK activation while
Bis I only partially inhibited ERK activation (Figure 6C). The specificity of these
inhibitors was confirmed by the demonstration that rottlerin had minimal effects
on PMA-induced ERK activation while Bis I completely inhibited PMA-promoted
ERK activation (Figure 6C). Taken together, we conclude that HEK293 cells
endogenously express the M3 mAchR and that carbachol-mediated activation of
the ERK1/2 cascade is dependent on PKC-δ.
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Figure 6. Charactrization of the Muscarinic Acetylcholine Receptor
Subtype Endogenously Expressed in HEK293 Cells
A) HEK293 cells loaded with the ratiometric calcium indicator Fura2/AM were
incubated with 100 nM pirenzepine (green), 1 µM p-FHHsiD (orange), vehicle
(red), or carbachol alone (black) and stimulated with 100 µM carbachol.
Changes in calcium mobilization were assayed by monitoring the change in Fura2AM fluorescence. Shown is a representative tracing from three independent
experiments. B) Following a 6 hr serum starve, HEK293 cells were incubated
with 100 nM pirenzepine, 1 µM p-FHHsiD, vehicle, or carbachol alone and
stimulated with 100 µM carbachol for the indicated times. Cells from a 6-well
plate were harvested and equal amounts of total cellular lysate were separated
by SDS-PAGE and probed for phospho-ERK1/2 as described in Materials and
Methods.

Shown is a representative immunoblot of three independent

experiments. C) Cells were treated with Bis I (2.5 µM), Bis V (2.5 µM) or rottlerin
(5 µM) for 30 min prior to stimulation with carbachol (100 µM) for 5 min or PMA
(100 nM) for 15 min.
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Regulation of M3 mAchR-mediated calcium mobilization in HEK293 cells
We next evaluated the effect of knocking down various regulatory proteins
on M3 mAchR signaling. Since the phosphorylation of activated GPCRs by
GRKs is often an early step in signal termination, we initially determined the
effect that GRK knockdown would have on calcium mobilization following
carbachol treatment. As shown in Figure 7A and 7B, we were able to selectively
and specifically knockdown each of the four individual GRKs expressed in
HEK293 cells. A modest increase in GRK3 expression was observed when other
GRKs, in particular GRK2, were knocked down (Figure 7B).
Knockdown of GRK2, GRK3, and GRK6 led to increases of 210%
(p<0.001), 190% (p<0.05) and 230% (p<0.001), respectively, in the peak calcium
transients, whereas knockdown of GRK5 had no effect on calcium mobilization
(Figure 8A and 8B). This effect was also observed when methacholine was used
to activate the M3 mAchR (data not shown). These data suggest that multiple
GRKs are involved in the desensitization of the M3 mAChR.

GRK2 interaction with Gq is primarily responsible for increased calcium
mobilization
The enhanced mobilization of calcium seen following silencing of GRK2
may arise from phosphorylation-dependent and/or phosphorylation-independent
mechanisms (Ribas et al., 2007). Therefore, we next sought to further delineate
the underlying mechanism observed for calcium mobilization when GRK2 was
knocked down. Because we showed previously that GRK2 interacts with Gαq
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Figure 7. Knock Down of Endogenous GRK Isoforms in HEK293 Cells
A) HEK293 cells were transfected twice within a 24 hr interval with GRK-specific
or non-specific control siRNA. 72 hr after the second transfection, cells were
harvested and equal amounts of total cellular lysate was separated by 10% SDSPAGE, transferred to nitrocellulose and incubated with the indicated antibodies.
Blots were stripped and re-probed for α-tubulin to control for loading. Shown is a
representative immunoblot. B) Mean relative level of GRK expression following
siRNA quantified by densitometry from five separate experiments.
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through the RGS-homology domain of GRK2 (Carman et al., 1999), the increase
in peak calcium mobilization could be a result of a loss of receptor
phosphorylation, a loss of the ability of GRK2 to inhibit activated Gaq, or both. To
address this, we generated cell lines that stably express either wild-type bovine
GRK2, kinase dead GRK2 (K220R), GRK2 point mutants defective in binding
Gaq (R106A, D110A), or a GRK2 mutant that was both kinase-dead and Gadeficient (R106A/K220R). Cloned cell lines expressing wild type or mutant
bovine GRK2 at levels close to endogenous GRK2 levels (1- to 5-fold
overexpression) were selected for study (Figure 8C). SDS-PAGE revealed that
bovine GRK2 ran slightly slower than endogenous human GRK2 when
expressed in HEK293 cells (Figure 8C). Stable expression of either wild type or
the kinase dead mutant reduced carbachol-stimulated calcium mobilization by
~50% (Figure 8D). In striking contrast, stable expression of the Gaq-binding
deficient mutants (R106A and D110A) or the double mutant (R106A/K220R) had
no effect on calcium mobilization (Figure 8D). This suggests that GRK2 primarily
regulates the activity of the M3 mAchR through its ability to interact with the
activated pool of Gaq.
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Figure 8. GRK-Mediated Regulation of Calcium Mobilization Following M3
Muscarinic Acetylcholine Receptor Activation
A) Effect on calcium mobilization. 72 hr after the second siRNA transfection,
HEK293 cells were loaded with Fura2/AM and stimulated with 10 µM carbachol.
B) Mean (+/- SEM) increase in the peak calcium transient following stimulation
with 10 µM carbachol from five individual experiments (*p<0.05, ***p<0.001 using
two-tailed T test). C) Representative immunoblot showing relative levels of
GRK2 stably expressed in HEK293 cells. D) Calcium mobilization in HEK293
cells stably expressing bovine GRK2. Mean (+/- SEM) increase in peak calcium
mobilization in cells expressing vector (pcDNA3), wild type, Gq-binding deficient
(R106A; D110A), kinase-dead (K220R), or the Gq-binding deficient/kinase dead
(R106A/K220R) bovine GRK2 (*p<0.05 for GRK2-K220R, ***p<0.001 for wild
type GRK2).
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The non-visual arrestins negatively regulate M3 mAchR-promoted calcium
mobilization
Our data suggest that GRK-mediated phosphorylation of the M3 mAchR
may contribute to subsequent desensitization. Because GRK phosphorylation
often promotes arrestin binding, we next determined the effect siRNA knockdown
of arrestin2 and arrestin3 had on calcium mobilization. Pooled siRNAs targeting
either arrestin2 or arrestin3 specifically reduced protein expression by ~90%
(Figure 9A and 9B). As shown in Figure 9, C and D, knockdown of either
arrestin2 or arrestin3 resulted in a significant increase in the peak calcium
transient upon stimulation with carbachol. The increase seen with arrestin3 was
slightly higher (74% increase) than that seen with arrestin2 (65% increase),
although silencing of arrestin3 also led to an increase in the prolonged phase of
the calcium transient (Figure 9C), suggesting prolonged IP3 production.

Regulation of M3 muscarinic acetylcholine receptor-mediated activation of
the ERK cascade
We next focused on understanding the roles of GRKs and arrestins in
regulating activation of ERK1/2 following M3 mAchR stimulation. The kinetics of
ERK1/2 activation showed a consistent peak at 5 min that returned to basal
levels by 60 min (Figure 6C). As shown in Figure 10, A and B, knocking down
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Figure 9. Effect of Arrestin Knockdown on Calcium Mobilization Following
M3 Muscarinic Acetylcholine Receptor Activation
A) Cells were transfected with SMARTpool siRNA and harvested 72 hr later.
Blots were incubated with a monoclonal antibody for arrestin2 that cross-reacts
with arrestin3. Blots were stripped and re-probed for α-tubulin to control for
loading. Shown is a representative immunoblot. B) Mean relative level of
arrestin expression following siRNA quantified by densitometry from five separate
experiments. C) Effect on calcium mobilization. Cells were harvested 72 hr posttransfection and processed as described previously. Shown is a representative
calcium trace from five independent experiments. D) Mean (+/- SEM) increase in
the peak calcium transient following stimulation with 100 µM carbachol from five
individual experiments (* p<0.05, ***p<0.001 using two-tailed T test).
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GRK2 resulted in a 2.5-fold increase in the peak of ERK1/2 activation and
prolonged ERK1/2 activation (Figure 10B). Silencing of GRK5 or GRK6 also
enhanced ERK1/2 activation following a 5-min stimulation, although the effects
were modest and not statistically significant (1.3- and 1.5-fold increase,
respectively) (Figure 10A and 10B). GRK knockdown did not change basal
phospho-ERK1/2 levels (data not shown). It is interesting that in contrast to
calcium mobilization, knocking down GRK3 had no effect on ERK1/2 activation
(Figure 10, A and B).

Collectively, these data demonstrate that signaling

pathways downstream of M3 mAchR activation are regulated by multiple GRKs in
HEK293 cells, in a separate but coordinated fashion.
In contrast to some GPCRs (Ahn et al., 2004; Lefkowitz and Shenoy,
2005), internalization is not required for M3 mAchR-mediated ERK activation
(Budd et al., 1999). Thus, it was not surprising that knockdown of either arrestin2
or arrestin3 resulted in an ~2-fold increase in ERK activation, with differential
temporal effects (Figure 10, C and D). Silencing of arrestin2 led to enhanced
ERK1/2 activation at 5 min, whereas silencing of arrestin3 led to both enhanced
and prolonged activation (Figure 10D). These data suggest that under normal
physiological conditions, either arrestin2 or arrestin3 is sufficient to negatively
regulate acute signaling events upon M3 mAchR activation, although arrestin3
appears to play a larger role in terminating signaling in response to prolonged
agonist exposure.
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Figure 10. Effect of GRK and Arrestin Knockdown on M3 Muscarinic
Acetylcholine Receptor ERK Activation
A) Effect of GRK knockdown on ERK1/2 activation. Following a 6 hour serum
starve, cells were treated with 100 µM carbachol for indicated times. Shown is a
representative immunoblot from six independent experiments. B) Mean fold
increase in ERK2 activation.

Blots were incubated simultaneously with

fluorophore conjugated primary antibodies specific for phospho-ERK1/2 and total
ERK2 overnight. Phospho-ERK1/2 fluorescence was normalized to total ERK2
fluorescence and data are presented as fold-increase in ERK2 activation over
basal (n=6, +/- SEM; *p<0.05, **p<0.01). C) Effect of arrestin knockdown on
ERK1/2 activation. Following a 6 hour serum starve, cells were treated with 100
µM carbachol for indicated times. Shown is a representative immunoblot from
eight independent experiments. D) Mean fold increase in ERK2 activation. Blots
were incubated simultaneously with fluorophore conjugated primary antibodies
specific for phospho-ERK1/2 and total ERK2 overnight.

Phospho-ERK1/2

fluorescence was normalized to total ERK2 fluorescence and data are presented
as fold-increase in ERK2 activation over basal (n=8, +/- SEM; **p<0.01).
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Regulation of the M3 muscarinic acetylcholine receptor by casein kinase 1α
CK1α also phosphorylates the M3 receptor in an agonist dependent
manner although it does not appear to be required for desensitization of the
receptor (Budd et al., 2000; Budd et al., 2001; Tobin et al., 1997). CK1α has also
been shown to phosphorylate the M1 mAchR and rhodopsin in vitro (Tobin et al.,
1997; Waugh et al., 1999). To determine whether CK1α has a role in regulating
the endogenous M3 mAchR, HEK293 cells were transfected with CK1α siRNA
that specifically reduced CK1α protein levels to ~40% of that seen in control cells
(Figure 11A). Knockdown of CK1α resulted in a significant increase (62%,
p<0.01, n=4) in the peak calcium transient compared to cells treated with control
siRNA (Figure 11B). To determine if this effect was specific to CK1α mediated
regulation of the M3 mAchR and not to some other aspect of the Gq signaling
pathway, we also tested the ability of CK1α to regulate the histamine H1 receptor
which is regulated by GRK2 in HEK293 cells (Iwata et al., 2005). Knockdown of
CK1α had no effect on calcium mobilization upon stimulation with 100 µM
histamine (data not shown), suggesting that the effect of CK1α knockdown was
specific for M3 mAchR signaling. Interestingly, knockdown of CK1α had no effect
on carbachol-mediated activation of ERK1/2 (Figures 11, C and D). These data
demonstrate that, in addition to the GRK family, the agonist activated M3 mAchR
is also regulated by CK1α.
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Figure 11. Effect of CK1α Knockdown on M3 Muscarinic Acetylcholine
Receptor Signaling
A) 72 hr after the second siRNA transfection, cells were harvested and equal
amounts of total cellular lysate were separated by SDS-PAGE and
immunoblotted for CK1α using a specific antibody. Blots were stripped and reprobed for α -tubulin to control for loading.

Shown is a representative

immunoblot. B) Effect on calcium mobilization. 72 hr after the second siRNA
transfection, cells were loaded with Fura-2/AM and stimulated with 100 µM
carbachol. Shown is a representative tracing from five independent experiments.
C) Effect on ERK1/2 activation. Following a 6 hr serum starve, cells were
stimulated with 100 µM carbachol for indicated times. Shown is a representative
immunoblot from eight independent experiments. D) Mean activation of ERK2.
Blots were incubated simultaneously with fluorophore conjugated primary
antibodies specific for phospho-ERK1/2 and total ERK2 overnight. PhosphoERK1/2 fluorescence was normalized to total ERK2 fluorescence and data are
presented as fold-increase over basal (n=8, +/- SEM).
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DISCUSSION
GPCRs transduce extracellular stimuli into specific intracellular signals
that regulate a variety of cellular functions. GPCR desensitization is classically
mediated by members of the GRK family, which specifically phosphorylate the
agonist-occupied receptor, promoting the subsequent high-affinity binding of
arrestins. For most GPCRs, the specificity of GRKs and arrestins in cells remains
poorly defined. In this report, we used a siRNA-based approach in HEK293 cells
to characterize the role of these proteins in M3 mAchR signaling. We found that
the M3 mAchR displays a complex pattern of regulation, such that GRK2, GRK3,
GRK6, arrestin2, arrestin3, and CK1α all participate to negatively regulate
calcium signaling upon receptor activation.
Previously, it was shown that GRK2 can be recruited to and phosphorylate
the M3 mAchR at two separate serine clusters within the third intracellular loop
(Wu et al., 2000). In addition to receptor phosphorylation, GRK2 is able to bind
both GTP-bound Gαq (Carman et al., 1999) and free Gβγ (Pitcher et al., 1992).
The crystal structure of GRK2 (Tesmer et al., 2005) suggests that it may
simultaneously sequester both active Gαq and free Gβγ, which in addition to
receptor phosphorylation may increase the strength and effectiveness of GRK2mediated receptor regulation. Previously, we and others demonstrated that
GRK2 regulated GPCRs, such as the H1 histamine (Iwata et al., 2005), M1
mAchR (Willets et al., 2005), metabotropic glutamate (Dhami et al., 2005) and
mouse cytomegalovirus GPCR M33 (Sherrill and Miller, 2006), involved the
regulation of Gq. Studies analyzing GRK-mediated regulation of the M3 mAchR in
82

SH-SY5Y cells have shown that GRK3 and GRK6 differentially regulate the
receptor whereas GRK2 and GRK5 did not appear to be involved (Willets et al.,
2001; Willets et al., 2002; Willets et al., 2003). Overexpressed GRK3 could
phosphorylate the M3 mAchR, however, GRK3-mediated regulation appeared to
be the result of altering the activity of PLC-β and not via receptor phosphorylation
(Willets et al., 2001; Willets et al., 2002; Willets et al., 2003). In contrast,
overexpressed GRK6 could phosphorylate the M3 mAchR leading to a decrease
in signaling. This effect was reversed upon expression of a kinase dead GRK6
(Willets et al., 2003).
Using siRNA coupled with stable expression of low levels of various GRK2
mutants, we found that the enhanced calcium mobilization observed upon GRK2
knockdown is primarily due to a loss in regulation of activated Gq following M3
mAchR stimulation (Figure 8). Furthermore, we showed that loss of GRK2 leads
to enhanced and prolonged activation of the ERK1/2 cascade (Figure 10). The
observed effects of GRK2 knock down are 2-fold: the enhanced calcium
mobilization seems to be primarily due to the loss of inhibition of activated Gq,
whereas the enhanced and prolonged activation of ERK1/2 probably reflects
enhanced DAG production/PKC-δ activation and a relief of inhibition of mitogen
activated protein kinase kinase 1 (MEK1) (Jiménez-Sainz et al., 2006). However,
we cannot completely rule out the possibility that GRK2 also mediates receptor
phosphorylation since endogenous M3 mAchR levels are too low to evaluate
phosphorylation (Tovey and Willars, 2004).
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We have also found that GRK3 and GRK6 negatively regulate calcium
mobilization following M3 mAchR stimulation. While knockdown of either kinase
led to significant increases in calcium mobilization (Figure 8A and 8B), silencing
of GRK3 had no effect on activation of ERK1/2 while loss of GRK6 had only a
minor effect (Figure 10A and 10B). The possibility exists that there is overlap
between these kinases and that regulation might involve a competition for
receptor binding as has been suggested for the angiotensin receptor (Kim et al.,
2005). These previous studies suggested that GRK2 and GRK3 negatively
regulate while GRK5 and GRK6 positively regulate ERK1/2 activation and that
differences in the phosphorylation pattern mediated by GRK2/3 or GRK5/6 could
alternatively promote the binding of arrestin2 or arrestin3, respectively (Kim et al.,
2005). However, our results suggest that the M3 mAchR is not subject to this
type of overlapping regulation. Furthermore, the GRKs do not play a positive role
in M3 mAchR signaling. There is a growing number of non-receptor substrates
that have been identified for the GRKs (Ribas et al., 2007), and in line with
previous findings, GRK3 could be primarily regulating PLC-β activity via binding
to Gβγ or Gαq (Willets et al., 2001). This might allow for a very rapid and robust
production of IP3 and subsequent calcium release that is not evident at later time
points because other kinases (e.g., GRK6) may phosphorylate the receptor
resulting in desensitization. In additional, mechanisms regulating downstream
signaling events (e.g., IP3 hydrolysis, calcium reuptake, etc) also shape both
calcium mobilization and ERK1/2 activation responses following carbachol
stimulation. As we have identified three GRKs that are involved in M3 mAchR
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regulation, multiple proteins may need to be knocked down simultaneously to
produce more prolonged signaling.
We reported previously that an ~50% reduction in arrestin levels using
antisense strategies had no effect on calcium mobilization in HEK293 cells
(Mundell and Benovic, 2000). In the present study, we were able to reduce
protein levels by ~90% and show that the loss of either arrestin2 or arrestin3
enhanced the peak calcium transient seen upon activation of the M3 mAchR
(Figure 9, C and D). Taking into consideration previous reports demonstrating
that the M3 mAchR internalizes in an arrestin-independent manner (Lee et al.,
1998), our results suggest that arrestins primarily mediate desensitization of the
M3 mAchR following agonist activation. Consistent with this and with previous
reports (Budd et al., 1999), knockdown of either arrestin2 or arrestin3 also
enhanced ERK1/2 activation (Figure 10, C and D). This is in contrast to the
emerging paradigm that has been proposed for a number of other GPCRs where
arrestins promote G protein-independent signaling pathways (reviewed in
Lefkowitz and Shenoy, 2005) or even have opposing effects to one another as
has been shown for the angiotensin II receptor (Ahn et al., 2004). In light of the
fact that HEK293 cells express similar levels of endogenous arrestin2 and
arrestin 3 (J.L.B, unpublished results), our data suggest an inherent specificity for
the M3 mAchR by arrestin3 as both calcium mobilization and ERK activation were
enhanced and prolonged with arrestin3 knockdown. This also suggests that the
PLC-β/PKC arm of signaling is responsible for ERK activation, consistent with
previous reports (Budd et al., 1999; Kim et al., 1999; Wylie et al., 1999). It is
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interesting that arrestins can also terminate muscarinic receptor signaling by
recruiting diacylglycerol kinases and enhancing the degradation of the second
messenger DAG, thereby coordinately terminating GPCR/G protein interaction
and second messenger generation (Nelson et al., 2007). Taken together, the
prolonged ERK activation observed following GRK2 and arrestin3 knockdown
can be attributed to enhanced Gq activity, sustained DAG production and
subsequent PKC-δ activation (Figure 12).
CK1α has a variety of functions within the cell (Knippschild et al., 2005)
and recently has been shown to regulate heterologously expressed M3 mAchR in
HEK293 and COS7 cells (Budd et al., 2000; Tobin et al., 1997). These studies
showed that CK1α phosphorylated the receptor in an agonist dependent manner,
and that deletion of a portion of the third intracellular loop or transient expression
of a dominant-negative CK1α construct caused an increase in IP3 production
upon receptor stimulation. Similarly, in the present study, we demonstrate that
CK1α knockdown results in enhanced calcium mobilization upon M3 receptor
activation, suggesting that CK1α is also involved in desensitization of
endogenous M3 mAchR in HEK293 cells. Knockdown of CK1α had no effect on
calcium mobilization upon H1 histamine receptor activation, demonstrating that
this effect was specific to the M3 mAchR. Previous studies have also shown that
expression of a peptide corresponding to the CK1α binding region or
overexpression of a mutated receptor lacking a portion of the third intracellular
loop led to a decrease in ERK1/2 activation upon receptor stimulation,
suggesting that CK1α-mediated phosphorylation was necessary for ERK
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activation (Budd et al., 2001). While we show that knockdown of CK1α has no
effect on ERK1/2 activation (Figure 11, C and D), indicating CK1α only plays a
partial role in regulation of M3 mAchR similar to GRK3 and GRK6, this may be
due to the fact that we only achieved ~60% knockdown of CK1α. It is interesting
to note that the peptide expressed in previous studies to sequester CK1α also
contained a portion of the Gβγ binding site of the third intracellular loop (Budd et
al., 2001; Wu et al., 2000). While free Gβγ was preferred, the heterotrimeric G
protein complex could also bind to this region (Wu et al., 2000). Therefore,
overexpression of this peptide could result in sequestration of the G protein,
decreasing activation of downstream signaling. The third intracellular loop of the
M3 mAchR contains 12 putative CK1α phosphorylation motifs (Tobin, 2002), two
of which overlap with the proposed GRK2 phosphorylation sites (Wu et al.,
2000). Thus, under physiological conditions, there could be competition between
these kinases for receptor binding and phosphorylation.
In this study, we demonstrate that multiple proteins coordinately regulate
the activity of the endogenous M3 mAchR in HEK293 cells (Figure 12).
Knockdown of GRK2, GRK3, GRK6, and CK1α, but not GRK5, enhanced
receptor calcium signaling, suggesting that multiple kinases regulate downstream
signaling following M3 mAchR activation. The effect of GRK2 on calcium flux
could be enhanced by both wild type and a kinase-dead mutant but not by Gaqbinding defective mutants demonstrating that GRK2 primarily regulates activated
Gq. Interestingly, only silencing of GRK2 led to both an enhanced and prolonged
ERK activation. Consistent with our findings that GRK2 primarily regulated Gq
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activity, this is likely a result of enhanced activation of the Gq/PLC-β/PKC-δ
signaling pathway. Finally, both arrestin2 and arrestin3 are involved in negatively
regulating the M3 mAchR as knockdown of either protein enhanced calcium
mobilization and ERK activation. Overall, our data suggest that multiple proteins
dynamically regulate M3 mAchR-mediated signal transduction.
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Figure 12. Regulation of the endogenous M3 mAChR in HEK293 cells
A) carbachol binding to the M3 mAChR results in activation of the Gq family of
heterotrimeric G proteins, leading to the dissociation of Gq and Gβγ. Activated Gq
activates PLC-β, resulting in the hydrolysis of phosphatidylinositol bisphosphate
(PIP2) to form the second messengers IP3 and DAG. IP3 interacts with the IP3
receptor located at the endoplasmic reticulum, resulting in a robust but transient
increase in cytosolic calcium. The formation of DAG recruits and activates the
novel PKC isoform PKC-δ. Once activated, PKC-δ leads to the activation of a
Ras-Raf-MEK-ERK1/2 cascade. B) phosphorylation of the M3 mAChR by GRK6
and possibly CK1α recruits arrestin2 and arrestin3 to the receptor, preventing
further G protein activation and terminating signaling. In addition, arrestins are
able to recruit diacylglycerol kinases (DGK) to the membrane and terminate the
PKC-dependent arm of the signaling cascade. GRK2 and GRK3, through a
conserved RGS domain, are able to interact with and sequester free Gq and
prevent activation of PLC-β. This results in the inhibition of both calcium
mobilization and activation of the ERK1/2 cascade. GRK2 is also able to regulate
the activation of the ERK1/2 cascade by interacting with and negatively
regulating the activity of MEK1.
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Chapter III
Site-specific phosphorylation of CXCR4 is
dynamically regulated by multiple kinases and
results in differential modulation of CXCR4
signaling
John M. Busillo and Jeffrey L. Benovic
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INTRODUCTION
CXCR4 is a widely expressed chemokine receptor that is essential for
development, hematopoiesis, organogenesis, and vascularization (Busillo and
Benovic, 2007).

CXCR4 also plays a prominent role in a number of diseases

including WHIM syndrome (Hernandez et al., 2003), HIV-1 entry (Feng et al.,
1996) and cancer progression and metastasis (Zlotnik, 2006). Interestingly,
WHIM syndrome is the direct result of C-terminal truncations of CXCR4 which
result in enhanced receptor function (Diaz and Gulino, 2005). Moreover, CXCR4
is expressed in at least 23 different types of cancer (Balkwill, 2004) and
accumulating evidence suggests that this results in dysregulation of CXCR4
transcription, signaling and trafficking (Busillo and Benovic, 2007).
Protein phosphorylation is the most prevalent post-translational
modification and plays a major role in regulating protein function (Cohen, 1992;
Manning et al., 2002). Importantly, phosphorylation is one of the earliest events
in regulating G protein-coupled receptor [GPCR] signaling, initiating a process
known as desensitization (Krupnick and Benovic, 1998; Pitcher et al., 1998).
Agonist-promoted desensitization is primarily mediated by members of the GPCR
kinase [GRK] family, which specifically phosphorylate agonist-occupied GPCRs
(Krupnick and Benovic, 1998; Pitcher et al., 1998; Gainetdinov et al., 2004). This
results in the recruitment and high affinity binding of arrestins, which function to
uncouple the receptor from G protein, target receptors for internalization, and
promote G protein-independent signaling (DeWire et al., 2007; Moore et al.,
2007).

While the specific protein kinases that mediate phosphorylation of
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individual GPCRs have not been well defined, site-specific and tissue-specific
phosphorylation of GPCRs likely have distinct effects on signaling (Tobin et al.,
2008).
Upon activation, CXCR4 is rapidly phosphorylated within its 45 amino acid
serine/threonine-rich C-terminal tail. Previous studies have suggested a number
of potential phosphorylation sites critical for agonist (CXCL12)- and PKCmediated receptor internalization (Signoret et al., 1998; Orsini et al., 1999) and
degradation (Marchese and Benovic, 2001). In addition, GRK2 (Orsini et al.,
1999; Cheng et al., 2000; Jiminez-Sainz et al., 2006), GRK3 (Balabanian et al.,
2008), GRK6 (Fong et al., 2002; Vroon et al., 2004), and PKC (Signoret et al.,
1997; Orsini et al., 1999) have been implicated in CXCR4 regulation, although
the sites of phosphorylation, the kinases involved in the phosphorylation of
specific sites, and the functional role of site-specific phosphorylation remain
largely unknown.
In order to better understand the role of phosphorylation in

regulating

CXCR4 signaling, we sought to identify agonist-promoted sites of
phosphorylation and the kinases that mediate site-specific phosphorylation.
Using liquid chromatography tandem mass spectrometry [LC/MS/MS] and
phospho-specific antibodies, we identified seven serine residues that are
phosphorylated in response to CXCL12 stimulation.

We show that

phosphorylation of these sites occurs with distinct kinetics and kinase specificity:
namely Ser-324/325 phosphorylation is rapid, transient and is primarily mediated
by PKC and GRK6; Ser-330 phosphorylation is delayed and is mediated by
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GRK6; and Ser-339 is phosphorylated rapidly by GRK6. Finally, we show that
GRK-mediated phosphorylation of CXCR4 and arrestin binding have differential
effects on calcium mobilization and ERK1/2 activation following CXCR4
activation.

RESULTS
Phospho-site mapping of CXCR4 by mass spectrometry
CXCR4 is rapidly phosphorylated and internalized following agonistactivation (Haribabu et al., 1997; Signoret et al., 1997; Orsini et al., 1999).
Truncation of the C-terminal tail of CXCR4, which contains 15 serine and 3
threonine residues, eliminates agonist-promoted phosphorylation, attenuates
internalization, and enhances receptor activity (Haribabu et al., 1997; Signoret et
al., 1997). Since alanine scanning mutagenesis suggested that multiple regions
of the C-tail may be phosphorylated following CXCL12 stimulation (Orsini et al.,
1999), we decided to use mass spectrometry to better define the specific sites
phosphorylated in CXCR4. We initially made a cell line stably expressing Flagtagged CXCR4 to enable rapid purification of the receptor, as previously
demonstrated for the β2-adrenergic receptor (β2AR) (Trester-Zedlitz et al., 2005).
HEK293 cells were chosen as a model cell because they express CXCR4
endogenously, though at very low levels (~20 fmol/mg membrane protein). A
clonally selected HEK293 cell line expressing Flag-tagged CXCR4 at ~0.5
pmol/mg (termed Flag CXCR4 cells) was chosen for further study. CXCL12
stimulation of endogenous CXCR4 in HEK293 cells resulted in robust calcium

101

mobilization and ERK1/2 activation (Figures 13A and B), although we were
unable to detect CXCL12-mediated inhibition of cAMP production or activation of
p38 or AKT (data not shown). Stable-expression of CXCR4 did not enhance
CXCL12-mediated calcium mobilization (Figure 13A) but did lead to an ~2.5 fold
increase in activation of ERK1/2 (Figure 13B).

In addition, as an indirect

measure of receptor phosphorylation, we looked at the ability of CXCL12 to
induce an electrophoretic mobility shift of CXCR4 on SDS-PAGE. Stimulation of
either HEK293 cells (Figure 13C) or Flag CXCR4 cells (Figure 13D) resulted in a
rapid retardation of electrophoretic mobility, consistent with receptor
phosphorylation. Thus, the Flag CXCR4 cells appear to be a good model system
in which to further characterize CXCR4 phosphorylation.
Mass spectrometry has become a valuable tool for identifying amino acids
that are post-translationally modified (Carr et al., 2005), a strategy recently
employed for the β2AR (Trester-Zedlitz et al., 2005). Since phosphorylation adds
~80 daltons [Da] to the molecular mass of a peptide, peptides with changes of 80
Da (or multiples thereof) from the theoretical mass can be identified, trapped and
subsequently fragmented by MS/MS to provide site-specific information on
phosphorylation (Carr et al., 2005). To identify sites of phosphorylation on
CXCR4, Flag CXCR4 cells were treated with CXCL12 for 10 min and the
receptor was then affinity purified on an anti-Flag column (Figure 14A). This
procedure resulted in ~80% recovery of the receptor and yielded ~0.5 mg of
purified CXCR4 per preparation (Figure 14B). Duplicate samples of purified
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Figure 13. Establishing and characterizing HEK293 cells that stably express
CXCR4
A) HEK293 cells or cells stably expressing Flag CXCR4 (Flag CXCR4 cells) were
loaded with the ratiometric calcium indicator Fura-2/AM prior to stimulation with
CXCL12 (100 nM).

The change in intracellular calcium was calculated by

monitoring the change in fluorescence of Fura-2/AM. Shown is a representative
trace of calcium mobilization from three independent experiments. B) Following
a 6 hr serum starvation, HEK293 cells or Flag CXCR4 cells were stimulated with
CXCL12 for the times indicated. Shown in a representative Western blot from
three independent experiments. CXCL12-promoted retardation of electrophoretic
mobility of endogenous CXCR4 (C) or Flag tagged CXCR4 (D). Following a 6 hr
serum starvation, cells were stimulated with 100 nM CXCL12 for the indicated
time.

Crude membranes were prepared and 50 µg of solubilized protein

(endogenous) or equal volume of whole cell lysate (Flag CXCR4) was separated
by 10% SDS-PAGE.

Shown is a representative Western blot from four

independent experiments.
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CXCR4 were then digested with either Lys-C or chymotrypsin and the resulting
peptides were subjected to LC/MS/MS. This identified peptides containing 38 of
the 45 C-terminal residues of CXCR4 including residues 310-328 and 334-352,
and several of the peptides were phosphorylated (Table 1). Figure 14C shows a
representative mass spectrum of a peptide (Thr-318 to Leu-328) obtained from a
chymotryptic digest, which contains five potential phosphorylation sites (Thr-318,
Ser-319, Ser-321, Ser-324, and Ser-325). The peak occurring with a mass ratio
of ~600 demonstrates that this peptide has two phosphates attached (M(H3PO4)2). The loss of phosphates upon fragmentation was apparent when Ser324 and Ser-325 were present in the fragment (see peaks b9-(H3PO4)2 and [b10(H3PO4)2]2+) but not in a peptide containing Thr-318, Ser-319 and Ser-321 (peak
b4), suggesting that both Ser-324 and Ser-325 are phosphorylated. These
results were confirmed from two separate experiments as well as with peptides
derived from Lys-C digestion (Table 1).

Since peptides containing Ser-325

phosphorylation alone were also observed, we speculate that Ser-325 is
phosphorylated before Ser-324 although we were unable to generate a pS325specific antibody to directly test this. Overall, these studies identified six sites of
phosphorylation following a 10 min stimulation with CXCL12: Ser-321, Ser-324,
Ser-325, one residue from Ser-338 to Ser-341, one residue from Ser-346 to Ser348, and either Ser-351 or Ser-352 (Figure 14D).

The specific sites of

phosphorylation that occur from Ser-338 to Ser-352 were not able to be
specifically determined by LC/MS/MS due to the serine-rich nature of this region.
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Figure 14. Purification and mass spectrometry analysis of CXCR4
A) Flag CXCR4 was purified from five 15-cm plates following a 10 min stimulation
with 50 nM CXCL12. The bulk of the receptor (~80%) elutes in fractions 2 and 3
and is highly purified as shown by Coomassie blue staining (B). C) Shown is a
representative mass spectrum of the peptide Thr-318 to Leu-328 following a
chymotrypsin digest demonstrating that CXCR4 is phosphorylated on Ser-324
and Ser-325. D) Amino acid sequence of the C terminal tail of CXCR4. Residues
highlighted in red are those that are predicted to be phosphorylated by mass
spectrometry. Brackets under Ser-338-Ser-341, Ser-346-Ser-348, and Ser351/Ser-352 indicate that one residue in each cluster is phosphorylated, though
the exact residue was not identified by mass spectrometry.
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Table 1
Lys-C Digestion

TSAQHALTSVSRGSSLK326

Predicted m/z
Ratio
1730

Observed m/z
Ratio
1730

TSAQHALTSVSRGSS*LK326

1730

1810

TSAQHALTSVSRGS*S*LK326

1730

1890

TSAQHALTSVS*RGSSLK326

1730

1810

TSAQHALTSVS*RGSS*LK326

1730

1890

RGGHSSVSTESESSSFHSS352

1952

1951

334

RGGHSSVSTESESSSFH[SS]352

1952

2031

334

1952

2031

334

1952

2031

Peptide
311
311
311

311
311
334

RGGHSSVSTESE[SSS]FHSS352
RGGH[SSVS]TESESSSFHSS352

Chymotrypsin Digestion

ALTSVSRGSSLKIL328

Predicted m/z
Ratio
1432

Observed m/z
Ratio
1432

ALTSVSRGSS*LKIL328

1432

1511

ALTSVSRGS*S*LKIL328

1432

1591

316

ALTSVSRGSSL326

1077

1077

ALTSVSRGSS*L326

1077

1157

TSVSRGSSLKIL328

1248

1248

TSVSRGS*S*LKIL328

1248

1408

KTSAQHALTSVSRGSSLKIL328

2084

Not observed

KTSAQHALTSVSRGS*S*LKIL328

2084

2244

Peptide
316
316
316

316

318
318
310
310

*

Denotes phosphorylated residues as predicted by LC/MS/MS

[ ] Denotes one of the highlighted residues is phosphorylated as predicted
by LC/MS/MS
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Protein kinase C is primarily responsible for phosphorylation of Ser-324/5
Previous mutagenesis studies have identified Ser-324/5 as critical for
CXCL12-induced internalization (Orsini et al., 1999) and degradation (Marchese
and Benovic, 2001) as well as PMA-promoted internalization (Signoret et al.,
1997; Orsini et al., 1999). To further characterize Ser-324/5 phosphorylation, we
generated a phospho-specific antibody to evaluate the kinetics of
phosphorylation and kinase-specificity for these residues. A 10 min stimulation
with CXCL12 results in robust phosphorylation of Ser-324/5 that was blocked by
pre-incubation with the immunizing phospho-peptide but not with vehicle or
unphosphorylated peptide (Figure 15A). Flag CXCR4 cells were then stimulated
for various times with CXCL12 and cell lysates were electrophoresed and blotted
with anti-pS324/5 to assess the kinetics of phosphorylation. Phosphorylation of
Ser-324/5 rapidly increased peaking at ~4-fold over basal within 5-10 min and
returned to near basal levels within 60 min (Figure 15B). Furthermore, the
increase in pS324/5 immuno-reactivity parallels the observed reduction in
electrophoretic mobility of CXCR4 following stimulation with CXCL12 (Figures
13D and 15B).
CXCR4, like other chemokine receptors, primarily couples to the Gi family
of heterotrimeric G proteins (Busillo and Benovic, 2007). In order to determine if
G protein activation was involved in receptor phosphorylation, cells were
pretreated with pertussis toxin prior to CXCL12 stimulation. Pertussis toxin
pretreatment significantly attenuated both the rate and extent of Ser-324/5
phosphorylation (Figure 15C). This suggests the possibility that activation of

109

second messenger dependent kinases such as PKC are largely responsible for
phosphorylation of these residues. Indeed, the primary amino acid sequence of
CXCR4 reveals that both Ser-324 and Ser-325 fall within a PKC consensus motif
(RGSSLK).
To initially address the role of PKC in agonist-promoted phosphorylation of
Ser-324/5, cells were pretreated with the broad-spectrum PKC inhibitor
Bisindolylmaleimide I [Bis I] or the negative control Bisindolylmaleimide V [Bis V]
(Toullec et al., 1991) prior to CXCL12 stimulation. Bis I treatment led to a
significant reduction in basal phosphorylation as well as CXCL12-promoted
phosphorylation of Ser-324/5 (Figure 16A). Since Bis I inhibits conventional and
novel PKC isoforms, we attempted to better define the PKC subtype(s) involved
in Ser-324/5 phosphorylation by pretreating cells with either Gö 6976, which
inhibits the conventional PKC isoforms (α, βI, and βII) (Martiny-Baron et al., 1993)
or rottlerin, which is reported to inhibit PKCδ (Gschwendt et al., 1994).
Treatment with rottlerin, but not with Gö 6976, led to a significant reduction of
Ser-324/5 phosphorylation (Figure 16B). However, since rottlerin can have offtarget effects (Soltoff, 2007), we attempted to confirm the role of PKCδ in CXCR4
phosphorylation using siRNA treatment.

PKCδ levels could be effectively

reduced in Flag CXCR4 cells by siRNA treatment and this resulted in a partial but
significant decrease in Ser-324/5 phosphorylation (Figure 16C). In contrast,
knock down of PKCα had no effect on Ser-324/5 phosphorylation (Figure 16C).
Taken together, these data demonstrate that PKC plays a major role in
phosphorylating Ser-324/5 following CXCL12 stimulation. The significant effect
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Figure 15. Characterization and pertussis toxin sensitivity of anti-pSer324/5 (pS324/5)
A) Shown is a representative Western blot demonstrating the specificity of the
pS324/5 antibody. 10 µg of purified antibody was incubated for 10 min with
vehicle (PBS), 10 µg of peptide (C-Ahx-RGSSLKIL) or 10 µg of phospho-peptide
(C-Ahx-RG(pS)(pS)LKIL) prior to overnight incubation with the nitrocellulose
blots. B) Cells stably expressing Flag CXCR4 were stimulated at the time points
indicated with 100 nM CXCL12. Lysates were processed and separated to
visualize the agonist promoted gel shift of CXCR4.

Blots were incubated

overnight with 1:1000 dilution of crude pS324/5 antibody.

pS3245 was

normalized to total CXCR4 and data is presented as fold increase over basal (±
S.E.M., n=4). C) Cells stably expressing Flag CXCR4 were treated overnight
with vehicle (PBS) or pertussis toxin (100 ng/ml) prior to stimulation with 100 nM
CXCL12. Left panel: representative Western blot using purified anti-pS324/5.
Right panel: pS324/5 was normalized to total CXCR4 and data is presented as
percent maximum of vehicle treated cells (± S.E.M., n=3; *p≤0.05, **p≤0.01,
***p≤0.001).
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Figure 16. PKC is primarily responsible for Ser-324/5 phosphorylation
following CXCL12 stimulation
A) Cells stably expressing Flag CXCR4 were serum starved for 6 hr. 30 min
prior to CXCL12 stimulation, cells were pretreated with 2.5 µM Bis I or Bis V. Left
panel: representative Western blot using crude anti-pS324/5 antibody. Blots
were processed as to visualize the gel shift.

Right panel:

pS324/5 was

normalized to total CXCR4 and data is presented as percent maximal Ser-324/5
phosphorylation compared to control (Bis V) (± S.E.M., n=4). B) To better define
the PKC isoforms responsible for CXCR4 phosphorylation, cells were pretreated
with vehicle (DMSO), 1 µM Gö 6976, or 5 µM Rottlerin for 30 min prior to
stimulation with CXCL12. Left panel: Representative Western blot using purified
anti-pS324/5 antibody. Right panel: pS324/5 was normalized to total CXCR4
and data is presented as percent maximal Ser-324/5 phosphorylation compared
to control (± S.E.M., n=4). C) Cells were treated with PKC-specific siRNAs. Left
panel: lysates were prepared 72 hr post-transfection and blotted for PKCα and
PKCδ as indicated.

Shown is representative Western blot demonstrating

efficiency and specificity of PKCα and PKCδ knock down. Right panel: 72 hr
post-transfection, cells were serum starved for 6 hr prior to stimulation with
CXCL12 (± S.E.M., n=4; *p≤0.05, **p≤0.01, ***p≤0.001).
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of Bis I pretreatment coupled with the fact that knock down of PKCδ only partially
decreases phosphorylation, suggests that PKCδ as well as additional PKC
isoforms likely mediate CXCR4 phosphorylation.

GRK6 contributes to Ser-324/5 phosphorylation
As some phosphorylation of Ser-324/5 is still evident following pertussis
toxin treatment or PKC inhibition, we hypothesized that GRKs also contribute to
phosphorylation of these residues. The GRKs consist of seven members, four of
which (GRK2, 3, 5, and 6) are expressed in HEK293 cells (Ren et al., 2005; Luo
et al., 2008). Since there are no specific GRK inhibitors available, we assessed
the effect of individual GRK knock down on Ser-324/5 phosphorylation. While
efficient and specific knock down of each of the individual GRKs expressed in
HEK293 cells was achieved (Figure 17A), only GRK6 knock down had a
significant effect on Ser-324/5 phosphorylation (Figure 17B). Since our results
suggest that both GRK6 and PKC contribute to Ser-324/5 phosphorylation, we
also evaluated the effect of PKC inhibition and GRK6 knock down. While PKC
inhibition or GRK6 knock down alone resulted in an ~50% or ~40% reduction in
phosphorylation, respectively, the combination resulted in an almost complete
loss of Ser-324/5 phosphorylation (Figure 17C). These data demonstrate that
both PKC and GRK6 are needed for maximal agonist-promoted phosphorylation
of Ser-324/5 following CXCL12 stimulation.
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Figure 17. GRK6 contributes to Ser-324/5 phosphorylation following
CXCL12 stimulation
A) Representative Western blot demonstrating specific and efficient knock down
of GRKs endogenously expressed in HEK293 cells 72 hr post-transfection. B)
Knock down of GRK6, but not GRK2, GRK3 or GRK5 led to a significant
reduction in phosphorylation of Ser-324/5. Left panel: representative Western
blot using purified anti-pS324/5.

Right panel: comparison of pS324/5

phosphorylation following a 5 min stimulation with CXCL12.

pS324/5 was

normalized to total CXCR4 and data is presented as percent of control at 5 min
(± S.E.M., n=4). C) GRK6 knock down and PKC inhibition almost completely
abolishes phosphorylation of Ser-324/5. Cells transfected with GRK6 siRNA
were pretreated with 2.5 µM Bis I or Bis V 30 min prior to stimulation with
CXCL12. Left panel: representative Western blot using purified anti-pS324/5.
Right panel: pS324/5 was normalized to total CXCR4 and data is presented as
percent maximal phosphorylation of Ser-324/5 as compared to control/Bis V
treated cells (± S.E.M., n=3; *p≤0.05, **p≤0.01, ***p≤0.001).
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Ser-330 and Ser-339 are phosphorylated by GRK6
Previous studies have demonstrated a prominent role of Ser-330 in
regulating CXCL12-promoted degradation (Marchese and Benovic, 2001) while
Ser-339 contributes to receptor internalization (Signoret et al., 1998; Orsini et al.,
1999). Although a peptide containing Ser-330 was not observed in our mass
spectrometry analysis, we generated and characterized a phospho-specific
antibody to this site.

In addition, a phospho-specific antibody has been

generated against Ser-339 (Woerner et al., 2005) and phosphorylation within this
region was also detected by mass spectrometry (Figure 14D).
Figure

18A,

both

Ser-330

and

As shown in

Ser-339 undergo agonist-promoted

phosphorylation, albeit with different kinetics. Phosphorylation of Ser-330 is
relatively slow peaking at ~20 min, whereas phosphorylation of Ser-339 is very
rapid peaking at ~2 min (Figure 18A).

Interestingly, despite the kinetic

differences, we found that both Ser-330 and Ser-339 are primarily
phosphorylated by GRK6 (Figures 18B and C).
Overall, we found that GRK6 phosphorylates multiple sites within the C
terminal tail of CXCR4 including Ser-324/5, Ser-330 and Ser-339 while GRK2, 3,
and 5 do not contribute to CXCR4 phosphorylation at these sites. Additional
studies demonstrate that PKC inhibition had no effect on CXCL12-promoted
phosphorylation of Ser-330 and Ser-339 (data not shown), demonstrating that
phosphorylation of these residues is completely GRK6-dependent in response to
CXCL12.
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Figure 18. Ser-330 and Ser-339 are GRK6 substrates
A) Cells expressing Flag CXCR4 were serum starved for 6 hr prior to stimulation
with 100 nM CXCL12 for times indicated. An equal volume of lysate was
separated by SDS-PAGE and blotted with purified anti-pS330 (top left panel) or
anti-pS339 (bottom left panel). pS330 blots were processed in order to visualize
gel shift of CXCR4.

Right panel: pS330 or pS339 blotting was normalized to

total CXCR4 and data presented as fold increase over basal (± S.E.M., n=4). B)
72 hr post-transfection, an equal volume of cell lysate was separated to visualize
the gel shift of CXCR4 and blotted using purified anti-pS330.

Shown are

representative Western blots of four separate experiments. C) 72 hr posttransfection, an equal volume of cell lysate was separated by SDS-PAGE and
blotted using anti-pS339. Shown are representative Western blots from four
separate experiments.
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GRKs differentially regulate CXCR4 signaling in HEK293 cells
Phosphorylation of GPCRs is one of the earliest mechanisms of
regulation, initiating the process of desensitization (Krupnick and Benovic, 1998).
Recent evidence suggests that differential phosphorylation of GPCRs can have
specific but disparate effects on receptor regulation (Kim et al., 2005; Ren et al.,
2005; Torrecilla et al., 2007; Luo et al., 2008).

Since CXCR4 activation in

HEK293 cells leads to calcium mobilization (Figure 13A) and activation of
ERK1/2 (Figure 13B), we next evaluated the functional role of GRKs in regulating
CXCR4-mediated signaling. Knock down of GRK2 or GRK6, but not GRK3 or
GRK5, led to a statistically significant increase in the peak calcium transient
observed following CXCL12 stimulation of endogenous CXCR4 in HEK293 cells
(Figure 19A). Interestingly, knock down of GRK2 led to an ~30% increase in
ERK1/2 activation while knock down of GRK3 or GRK6 led to an ~40% reduction
in ERK1/2 activation (Figures 19B and C). In contrast, inhibition of PKC by Bis I
had no effect on activation of ERK1/2 following CXCL12 activation (data not
shown).
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Figure 19. GRKs differentially regulate signaling following activation of
endogenous CXCR4 in HEK293 cells
A) HEK293 cells were loaded with the ratiometric calcium indicator Fura-2A/M 72
hr after siRNA transfection. Cells were stimulated with 100 nM CXCL12 and
changes in intracellular calcium were calculated from changes in fluorescence.
Left panel: shown is a representative trace from six separate experiments. Right
panel: mean (± S.E.M.) increase in peak calcium transient calculated from six
separate experiments. B) Effect of GRK knock down on CXCL12-mediated
activation of ERK1/2. 72 hr post-transfection, cells were serum starved for 6 hr
prior to stimulation with CXCL12 (100 nM). Shown is a representative Western
blot from five independent experiments. C) Left panel: pERK2 was normalized to
total ERK2 and data are presented as percent maximal ERK2 activation as
compared to control (± S.E.M., n=4). Right panel: comparison of maximal ERK2
activation (5 min) following stimulation with CXCL12 (100 nM) (± S.E.M., n=4;
*p≤0.05, **p≤0.01, ***p≤0.001).
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We also evaluated whether the stable over-expression of CXCR4 altered
GRK-mediated regulation. Similar to endogenous CXCR4, knock down of either
GRK2 or GRK6 in the Flag CXCR4 cells enhanced calcium mobilization,
although GRK6 had the larger effect (Figure 20A). Similarly, knock down of
GRK2 enhanced while knock down of GRK3 or GRK6 decreased activation of
ERK1/2 (Figures 20B and C).

Thus, stable over-expression of CXCR4 in

HEK293 cells did not alter the signaling or regulation of CXCR4. Our data
suggest that phosphorylation of CXCR4 by GRK6 and possibly GRK2 uncouples
the receptor from activation of Gi, decreasing calcium mobilization. In contrast,
GRK3 and GRK6-mediated phosphorylation of CXCR4 positively regulates
activation of ERK1/2.
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Figure 20. Differential GRK-mediated regulation is conserved in Flag
CXCR4 cells
Cells expressing Flag CXCR4 were analyzed for calcium flux (A) and ERK1/2
activation (B and C) exactly as described in the legend to Figure 19.
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Arrestins differentially regulate signaling following CXCR4 activation
Agonist-dependent phosphorylation of many GPCRs leads to the
recruitment of the non-visual arrestins, arrestin2 and arrestin3 (also termed βarrestin1 and β-arrestin2, respectively), which effectively uncouples the receptor
from heterotrimeric G proteins as well as targeting the receptor for internalization
(Moore et al., 2007). Recent evidence has highlighted the ability of arrestins to
nucleate signaling events in addition to their classical role in desensitization
(DeWire et al., 2007). Therefore, we next examined the effect of siRNA-mediated
knock down of arrestin2 and 3 on CXCR4 signaling in HEK293 cells. Knock
down of arrestin3 led to a significant increase, whereas arrestin 2 had only a
modest effect, in the peak calcium transient observed following CXCL12
stimulation of endogenous (Figure 21A) or overexpressed CXCR4 (Figure 21B).
Conversely, knock down of arrestin2 led to a significant reduction in ERK1/2
activation following CXCL12 stimulation of endogenous (Figure 21C) or
overexpressed (Figure 21D) CXCR4, while knock down of arrestin3 had lesser
effects. These results reveal that both arrestins contribute to regulating CXCR4
signaling although arrestin3 appears to play the primary role in desensitization of
calcium mobilization while arrestin2 plays the primary role in activation of ERK1/2
signaling.
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Figure 21. Non-visual arrestins differentially regulate CXCR4-mediated
signaling
A) Mean (± S.E.M.) increase in peak calcium transient following stimulation of
endogenous CXCR4 calculated from seven separate experiments. B) Mean (±
S.E.M.) increase in peak calcium transient following stimulation of Flag CXCR4
calculated from three separate experiments. C and D) Effect of arrestin knock
down on ERK1/2 activation following activation of HEK293 (C) or Flag CXCR4
(D) cells. 72 hr post-transfection, cells were serum starved for 6 hr prior to
stimulation with CXCL12 (100 nM).

Left panels: shown are representative

Western blots from seven (C) and four (D) separate experiments. Right panels:
pERK2 was normalized to total ERK2 and data is presented as percent maximal
ERK2 activation as compared to control (± S.E.M.; *p≤0.05, **p≤0.01,
***p≤0.001).

128

DISCUSSION
Phosphorylation has long been recognized as an initiating step in the
process of GPCR desensitization (Krupnick and Benovic, 1998; Pitcher et al.,
1998). Characterizing the mechanisms involved in receptor regulation under
“normal” physiological conditions will add significantly to our understanding of
receptor signaling as well as receptor dysregulation in disease. CXCR4 has
emerged as a prominent GPCR due to its reported role in cancer progression
and metastasis (Zlotnik, 2006) and recent studies have provided evidence for the
dysregulation of CXCR4 in cancer cells (Li et al., 2004; Slagsvold et al., 2006).
Given the wealth of knowledge on the role of CXCR4-mediated signaling in
cancer (Kucia et al., 2005), it is surprising that the regulation of CXCR4 function
is not better understood. In this report, we characterize site-specific
phosphorylation of CXCR4 and provide evidence that kinase-specific
phosphorylation has distinct effects on CXCR4 signaling.
Since mutagenesis and metabolic labeling studies have suggested that
multiple regions of the C terminal tail of CXCR4 may be phosphorylated (Orsini et
al., 1999), we used mass spectrometry and phospho-specific antibodies to define
specific sites of phosphorylation.

Using these approaches we found that

CXCL12 promotes the phosphorylation of 7 serines in the C terminal tail (Figure
14D), although we cannot rule out the presence of additional sites. We confirmed
previous studies suggesting that Ser-324 and Ser-325 are phosphorylated
(Signoret et al., 1998; Orsini et al., 1999) as well as one study showing that Ser339 is phosphorylated (Woerner et al., 2005) (Figure 15C and D). In addition, we
found that Ser-321 is phosphorylated, a site that has not been previously
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implicated in CXCR4 regulation, and we demonstrated that Ser-330 is also
phosphorylated in response to CXCL12 (Figure 18A).
Phospho-specific antibodies have provided a powerful tool to enable
characterization of phosphorylation kinetics for a number of GPCRs (Pollok-Kopp
et al., 2003; Schulz et al., 2004; Tran et al., 2004). Here, we successfully used
phospho-specific antibodies against Ser-324/5, Ser-330 and Ser-339 and found
that phosphorylation at these sites occurs with disparate kinetics, peaking at 5-10
min, ~20 min, and ~2 min following CXCL12 stimulation, respectively. Based on
these results, we hypothesize that phosphorylation at these sites would have
distinct effects on desensitization, signaling, and/or trafficking following CXCR4
activation. In this regard, previous studies have suggested that Ser-324/5 and
Ser-330 play an important role in CXCR4 degradation (Marchese and Benovic,
2001) while CXCR4 recycles to the plasma membrane with varying efficiencies in
different cell lines (Amara et al., 1997; Tarasova et al., 1998; Marchese et al.,
2003; Venkatesan et al., 2003). These findings suggest cell type differences in
Ser-324/5 or Ser-330 phosphorylation may regulate differential CXCR4 sorting.
These phospho-specific antibodies should enable a more in-depth analysis of
CXCR4 phosphorylation in various tissues and cells.
To address if site-specific phosphorylation can differentially dictate the
regulation of CXCR4 signaling, we evaluated the role of site- and kinase-specific
phosphorylation in CXCR4-mediated signaling. We provide evidence for PKCδ in
selectively phosphorylating Ser-324/5 following CXCL12 stimulation with no
effect on Ser-330 or Ser-339 (Figure 16 and data not shown). Previously, PKC
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has been thought to be primarily involved in heterologous desensitization of
CXCR4, downstream of a number of receptors (Busillo and Benovic, 2007).
Interestingly, Ser-324 and Ser-325 have been shown to play a prominent role in
PKC-mediated internalization of CXCR4 (Signoret et al., 1998; Orsini et al.,
1999), although there have been conflicting reports for the role of these residues
in CXCL12-mediated internalization. For example, mutation of Ser-324/5 to
alanine had no effect on internalization in Mv-1-Lu cells (Signoret et al., 1998) but
effectively attenuated internalization in HEK293 cells (Orsini et al., 1999). Since
Ser-324/5 is robustly phosphorylated following CXCL12 stimulation in HEK293
cells, cell type dependent differences in trafficking may be attributed to
differences in phosphorylation or in subsequent protein/protein interactions. In
addition, since PKC inhibition had no effect on CXCR4 activation of ERK1/2 (data
not shown), Ser-324/5 phosphorylation does not appear to participate in CXCR4
signaling or in arrestin recruitment (discussed below).
GRK6 was found to contribute to Ser-324/5 phosphorylation and be
principally responsible for Ser-330 and Ser-339 phosphorylation (Figures 17 and
18). While no GRK-specific phosphorylation motifs have been identified, GRK2
and 3 prefer acidic residues N terminal to the phosphorylation site while GRK5
and 6 prefer basic residues (Pitcher et al., 1998). Consistent with our GRK6
results, there are basic residues located N terminally to Ser-324/5, Ser-330 and
Ser-339 (Figure 14D). Previous studies have shown that the deletion of GRK6 in
a mouse had marked effects on the activity of CXCR4, leading to enhanced
function and a lack of desensitization (Fong et al., 2002; Vroon et al., 2004).
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Surprisingly, loss of GRK6 had different effects on CXCL12-mediated chemotaxis
in neutrophils and T cells, suggesting that the regulation of CXCR4 function by
phosphorylation may be cell type dependent (Fong et al., 2002; Vroon et al.,
2004). While these previous studies did not evaluate signaling, our work has
shown that loss of GRK6 significantly increased calcium mobilization while
reducing ERK1/2 activation. We propose that GRK6-mediated phosphorylation
of CXCR4 plays an essential role in the recruitment of arrestins to the receptor as
discussed below.
Two residues at the extreme C terminus of CXCR4 (one between Ser346-348 and either Ser-351 or Ser-352) are also phosphorylated in response to
CXCL12 stimulation (Figure 14D). Based on the acidotropic nature of these
serines, we postulate that these residues are phosphorylated by GRK2 and/or
GRK3 (Figure 14D).

Interestingly, recent studies suggest that GRK3

phosphorylates the far C-terminal region of CXCR4 (Balabanian et al., 2008).
Over-expression of GRK3 enhanced internalization of wild type CXCR4 but not a
C-terminally truncated CXCR4 lacking the last 15 amino acids (which contains 10
serines and threonines). Since previous work has demonstrated that Ser-338 is
not phosphorylated in response to CXCL12 (Woerner et al., 2005) and we have
shown that Ser-339 is phosphorylated by GRK6 (Figure 18C), we speculate that
GRK3 is responsible for phosphorylating a serine within the Ser-346-348 cluster
as well as either Ser-351 or Ser-352 in response to CXCL12 stimulation.
Furthermore, as knock down of GRK3 had no effect on calcium mobilization but
significantly decreased ERK1/2 activation (Figures 19 and 20), we propose that
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GRK3-mediated phosphorylation of C-terminal residues acts in concert with
GRK6-mediated phosphorylation to participate in ERK1/2 activation by stabilizing
CXCR4 interaction with arrestin (Figure 22).
Interestingly, we found that GRK2 negatively regulates CXCR4-mediated
activation of both calcium flux and ERK1/2 (Figures 19 and 20). Previous overexpression studies showed that GRK2 enhances CXCR4 internalization (Orsini
et al., 1999; Cheng et al., 2000) and negatively regulates CXCL12-mediated ERK
activation downstream of the receptor in HEK293 cells, possibly through
interaction with MEK (Jimenez-Sainz et al., 2006). While we cannot rule out the
possibility that GRK2 directly phosphorylates CXCR4, we hypothesize that the
observed effects of GRK2 knock down occur downstream of CXCR4. This could
include interaction with free Gβγ (Pitcher et al., 1992; Carman et al., 1998),
resulting in inhibition of Gβγ-mediated activation of PLC-β (Camps et al., 1992)
and the observed increase in calcium mobilization when GRK2 levels are
reduced. In addition, GRK2 inhibition of MEK would result in enhanced ERK1/2
activation when GRK2 levels are reduced (Jimenez-Sainz et al., 2006). It is also
possible that there may be tissue specific differences in site-specific
phosphorylation of CXCR4 by GRK2 and GRK3.
The positive role of GRK3 and GRK6 on ERK1/2 activation prompted us to
evaluate the role of arrestins in CXCR4 signaling.

Previous studies have

suggested that arrestin3 is involved in desensitization, internalization, and
activation of p38 and ERK1/2 (Orsini et al., 1999; Cheng et al., 2000; Fong et al.,
2002; Sun et al., 2002), whereas arrestin2 is involved in sorting CXCR4 to the
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lysosomes for degradation (Bhandari et al., 2007). Similar to studies on the
angiotensin and vasopressin receptors (Ahn et al., 2004; Ren et al., 2005), we
have found that arrestin2 and arrestin3 have different effects on CXCR4
signaling. Our results suggest that arrestin3 plays a primary role in desensitizing
G protein activation (i.e., inhibiting calcium mobilization), a pathway that appears
dependent on GRK6 phosphorylation of CXCR4. Conversely, arrestin2 plays a
positive role in ERK1/2 activation and appears to require phosphorylation of the
receptor by both GRK3 and GRK6. This pattern of arrestin-mediated activation
of ERK1/2 is somewhat unique since most GPCRs either require both arrestins
(DeWire et al., 2007) or arrestin3 (Ahn et al., 2004; Ren et al., 2005) for ERK
activation although there is one report that PAR1 selectively utilizes arrestin2
(Kuo et al., 2006). In addition, the involvement of multiple GRKs in receptor
regulation is analogous to studies on the β 2AR where GRK2- and GRK6mediated phosphorylation mediates arrestin3 binding, although GRK6 plays the
prodominant role (Violin et al., 2006).

We hypothesize that the observed

decrease in ERK activation is likely due to a decrease in the extent of arrestin2
recruitment with GRK3 or GRK6 knock down and the inability to form a stable
CXCR4-arrestin2 complex (Tohgo et al., 2003; Jafri et al., 2006).

Another

possibility is that CXCR4 phosphorylation by GRK3 and GRK6 allows arrestin2 to
adopt a conformation (Kim et al., 2005; Ren et al., 2005) that allows for full
activation of ERK1/2.
In summary, our results support a model where GRK6-mediated
phosphorylation leads to recruitment of arrestin3 (Figure 22). This serves to
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uncouple CXCR4 from activation of Gi thereby regulating calcium release. In
contrast, GRK3- and GRK6-mediated phosphorylation of CXCR4 promotes
interaction with arrestin2 and results in full activation of ERK1/2. GRK2, on the
other hand, likely attenuates calcium release and activation of ERK1/2 through its
interaction with Gβγ and MEK, respectively. While we cannot specifically pinpoint
the phosphorylation sites that mediate differential arrestin association, the finding
that PKC inhibition does not affect ERK1/2 activation suggests that Ser-324/5
phosphorylation does not contribute to arrestin binding. These results provide a
foundation to better understand how CXCR4 is regulated and identify distinct
regulatory molecules that can be targeted to modulate CXCR4 signaling in
disease.
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Figure 22. Regulation of CXCR4 activity and signaling
Upon activation, CXCR4 is phosphorylated on seven residues: Ser-321, Ser-324,
Ser-325, Ser-330, Ser-339, a residue from Ser-346-S348, and either Ser-351 or
Ser-352.

We propose that GRK6-mediated phosphorylation results in the

recruitment of arrestin3 to CXCR4, thereby attenuating G protein activation and
calcium release. GRK2 also attenuates G protein activation and calcium release
most likely by regulating Gβγ activation of PLCβ.

We also propose that

phosphorylation by GRK3 and GRK6 results in more stable interaction with
arrestin2 allowing for activation of ERK1/2. In contrast, GRK2 inhibits ERK1/2 by
regulating the activity of MEK. Although robustly phosphorylated by PKC and, to
a lesser extent by GRK6, phosphorylation of Ser-324/5 does not contribute to
signaling.
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EXPERIMENTAL PROCEDURES
Cell culture and RNAi transfections
HEK293 cells (Microbix, Toronto, Canada) were maintained in complete
Dulbecco’s modified Eagle’s media [DMEM] with 10% fetal bovine serum and 25
mM HEPES, pH 7.4.

Cells stably expressing CXCR4 were selected and

maintained in complete DMEM supplemented with 0.8 mg/ml G418 and
penicillin/streptomycin. HEK293 cells were plated in fresh complete DMEM 24 hr
prior to RNAi transfection.

All siRNAs were synthesized by Dharmacon

(Lafayette, CO) with the ON-TARGET plus modification. Four separate siRNAs
were reconstituted and pooled at a final concentration of 15 pmol/µl. GRKs were
targeted

against

the

following

sense

strands:

GRK2

–

5’

GGGACGUGUUCCAGAAAUU 3’; 5’ GCUCGCAUCCCUUCUCGAA 3’; 5’
GGAAUCAAGUUACUGGACA 3’; 5’ GCAAUAAGUUCACACGGUU 3’; GRK3 –
5’ GGAGUGUGAUGCAGAAGUA 3’; 5’ GAGGAUACCAAAGGGAUUA 3’; 5’
GGGAAGGACUGUAUUAUGC 3’; 5’ GAACACGUACAAAGUCAUU 3’; GRK5 –
5’CCAACACGGUCUUGCUGAA 3’; 5’ GGGAGAACCAUUCCACGAA 3’;
CAAACCAUGUCAGCUCGAA 3’; 5’ GAUUAUGGCCACAUUAGGAUU 3’; GRK6
– 5’GGUGAAGAAUGAACGGUAC 3’; 5’ GAGCUUGGCCUACGCCUAU 3’;
GCACGUAACGCAGAAUUUU 3’; 5’ CGCCAAGAUUGCUGUGGAA 3’. PKCδ
was

targeted

against

the

following

sense

strands:

5 ’

CCAUGAGUUUAUCGCCACC 3’; 5’ CAGCACAGAGCGUGGGAAA 3’. The
arrestin and PKCα siRNAs have been previously described (Luo et al., 2008;
Oliva et al., 2008). The PKC siRNAs were reconstituted individually at 60
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pmol/µl. Prior to transfection, 300 pmol of each were combined for a total of 600
pmol/transfection. Non-targeting siRNA pooled control modified with the ONTARGET plus modification was used for all experiments. HEK293 cells, ~65 to
70% confluent, were transfected with 600 pmol of siRNA using Lipofectamine
2000 (Invitrogen) in OPTI-MEM (Invitrogen) per the manufacturer’s instructions.
Cells were maintained in low-serum media for 4 hr, at which point an equal
volume of 2X complete media (20% FBS and 25 mM HEPES) was added. Cells
were split 48 hours post-transfection for assay the following day.

Purification of Flag CXCR4
Purification of Flag-tagged CXCR4 was performed as previously described
for the β2AR (Trester-Zedlitz et al., 2005) with minor modifications. Cells grown
to ~90% confluency in five 15-cm plates were washed twice with phosphate
buffered saline [PBS]. Cells were then incubated in serum free DMEM media
[SFM] for 6 hr, the media was aspirated, and replaced with fresh SFM containing
50 nM CXCL12 for 10 min. Cells were scrapped into 10 ml of hypotonic lysis
buffer (20 mM Tris-HCl, pH 7.5, 2.5 mM CaCl2, 10 mM NaF, and one Complete
Protease inhibitor tablet (EDTA-free)) and lysed by 10 strokes in a Dounce
homogenizer (tight pestle). Membranes were pelleted by centrifugation at 40,000
x g for 20 min at 4°C. Pellets were resuspended in 10 ml of Buffer A (20 mM
Tris-HCl, pH 7.5, 100 mM NaCl, 10 mM NaF, 1% dodecyl maltoside [DDM], 2.5
mM CaCl2, and one Complete protease inhibitor tablet (EDTA-free)) and
homogenized by 20 strokes in a Dounce homogenizer.
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Cellular debris was

cleared by centrifugation at 40,000 x g for 20 min at 4°C.

The resulting

supernatant was passed over an M1 anti-flag affinity (Sigma-Aldrich, St Louis
MO) column (0.4 ml resin/10 ml of lysate, flow rate of 5 ml/hr) equilibrated in
Buffer B (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% DDM, 2.5 mM CaCl2) at
room temperature. The column was washed once with 5 ml of Buffer C (20 mM
Tris-HCl, pH 7.5, 300 mM NaCl, 0.1% DDM, 2.5 mM CaCl2) at a rate of 10 ml/hr
followed by an additional wash with 5 ml of Buffer B. Bound receptor was then
eluted from the column in Buffer D (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1%
DDM, 200 µM Flag peptide, 1 µM AMD 3100, 10 mM EDTA) in 1 ml fractions and
immediately snap frozen in liquid nitrogen and stored at –80°C. Fractions
containing CXCR4 (by Western blot) were concentrated using Microcon ultracell
YM-10 concentrators (Millipore Cooperation, Billerica, MA). Purified CXCR4 was
electrophoresed on a 4-20% SDS-Glycine gradient gel (Invitrogen, Carlsbad CA),
stained with Coomassie blue, de-stained, excised and shipped on ice for
LC/MS/MS analysis.

LC/MS/MS procedure
Gel pieces were transferred to siliconized tubes, washed and destained
overnight in 200 µl of 50% methanol.

The gel pieces were dehydrated in

acetonitrile and then rehydrated in 30 µl of 10 mM dithiothreitol [DTT] in 0.1 M
ammonium bicarbonate and incubated at room temperature for 30 min. The DTT
solution was removed and the sample was alkylated in 30 µl of 50 mM
iodoacetamide in 0.1 M ammonium bicarbonate at room temperature for 30 min.
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The gel pieces were dehydrated in 100 µl of acetonitrile, rehydrated in 100 µl of
0.1 M ammonium bicarbonate, dehydrated in 100 µl of acetonitrile, completely
dried by vacuum centrifugation and then rehydrated in 20 µl of 50 mM
ammonium bicarbonate containing 20 ng/µl Lys-C or chymotrypsin and incubated
overnight at 37oC. Peptides were extracted from the polyacrylamide in two 30 µl
aliquots of 50% acetonitrile/5% formic acid and the extracts were combined and
evaporated to 15 µl for MS analysis.
The LC/MS system consisted of a Thermo Electron LTQ-FT mass
spectrometer system with a Protana nanospray ion source interfaced to a selfpacked 8 cm x 75 µm id Phenomenex Jupiter 10 µm C18 reversed-phase
capillary column. Extract (1-5 µl) was injected and peptides eluted from the
column using an acetonitrile/0.1 M acetic acid gradient at a flow rate of 0.25
µl/min. The nanospray ion source was operated at 2.8 kV. The digest was
analyzed using the double play capability of the instrument acquiring full scan
mass spectra (ICR; 100K resolution) to determine peptide molecular weights and
five product ion spectra (ion trap) to determine amino acid sequence in
sequential scans. This mode of analysis produces approximately 1500 CAD
spectra of ions ranging in abundance over several orders of magnitude. The
data were analyzed by database searching using the Sequest search algorithm
against CXCR4. Putative phosphorylated peptides were confirmed by manual
analysis.
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Generation of polyclonal antibodies specific for pS324/5 and pS330
Polyclonal antibodies specific for pS324/5 and pS330 were generated by
Open Biosystems (Huntsville, AL).

Briefly, peptides corresponding to

phosphorylated CXCR4 at Ser-324/5 (C-Ahx-RG(pS)(pS)LKIL where Ahx is
amino hexonic acid) and Ser-330 (CLKIL(pS)KGKRGGH) were synthesized,
coupled to hemocyanin and used to immunize rabbits following a standard
immunization protocol. Crude sera from each rabbit was collected at days 28, 56
and 72 following primary immunization and tested for immuno-reactivity.
Antibody was purified from pooled bulk sera (days 56 and 72) from animal E5199
(pS324/5) and E5198 (pS330) using the immunizing peptide, concentrated to 1
mg/ml, and aliquots were stored at –80°C. Antibody specificity was evaluated by
preincubating 10 µg of purified antibody with vehicle (PBS), 10 µ g of the
immunizing peptide or 10 µg of the non-phosphorylated peptide.

Calcium mobilization and ERK1/2 activation
Calcium mobilization was performed as previously described (Luo et al.,
2008). For analyzing ERK1/2 activation, cells were plated into 6-well plates 24 hr
prior to stimulation. Confluent cells were washed twice with PBS and maintained
in 1 ml of SFM for 6 hr at 37°C prior to stimulation. Following stimulation, media
was aspirated on ice and cells were lysed by the addition of 300 µl of 2x SDS
sample buffer and stored at –80°C until processed. Lysates were thawed on ice,
sonicated for 10 sec (10% amplitude) and allowed to sit at room temperature for
30 min prior to electrophoresis. Equal volumes were separated by 10% SDS-
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PAGE, transferred to nitrocellulose, blocked with ODYSSEY® blocking buffer (LiCor® Biosciences) and blotted overnight with a mixture of anti-phospho-p42/44
(Cell Signaling Technologies, Boston MA) and anti-ERK2 (Santa Cruz, Santa
Cruz, CA). The following day, blots were washed extensively with Tris Buffered
Saline containing 0.1% Tween-20 [TBS-T], incubated with a mixture of goat antirabbit Alexa® Fluorophore 680 conjugated (Molecular Probes) and goat antimouse IRDye 800 conjugated secondary (Rockland Immunochemicals)
antibodies (1:5000) for 1 hr at room temperature. Blots were washed extensively
with TBS-T and visualized using the ODYSSEY® infrared imaging system (LiCor® Biosciences).
Detection of pS324/5, pS330 and pS339
HEK293 cells stably expressing Flag CXCR4 were stimulated and
processed as described for ERK1/2 activation. An equal volume of cell lysate
was separated by 10% SDS-PAGE, transferred to nitrocellulose and blocked for
1 hr in 0.25% gelatin. Blots were incubated overnight at 4°C with a mixture of
anti-CXCR4 (BD Bioscience) and anti-pS324/5, anti-pS330, or anti-pS339
primary antibodies. Blots were extensively washed with TBS-T and incubated
with a mixture of goat anti-rabbit Alexa® Fluorophore 680 conjugated (Molecular
Probes) and goat anti-rat IRDye 800 conjugated secondary (Rockland
Immunochemicals) antibodies for 1 hr at room temperature. Blots were
developed as described above for phospho-ERK. Phospho-CXCR4 was then
normalized to total CXCR4 and is represented as percent maximum. For assays
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with PKC inhibition, cells were pretreated with vehicle (DMSO) or appropriate
inhibitor for 30 min prior to stimulation with CXCL12.

Electrophoretic mobility shift assay
An equal volume of cell lysate was separated by 10% SDS-PAGE for 1 hr
40 min at ~135V, transferred to nitrocellulose and blocked for 1 hr in 5% milk in
TBS-T. Blots were subsequently probed for CXCR4 as described above for
phospho-CXCR4.

Statistical Analysis
All data are represented as the mean ± standard error of the mean
[S.E.M.]. Data were analyzed using a two-tailed student’s t-test with significance
set at p≤0.05.
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Chapter IV
Discussion
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Being one of the largest families of cell surface receptors, GPCRs are
critically involved in nearly every physiological process.

Accordingly, strict

regulatory mechanisms need to be in place to ensure proper spatial and temporal
control of receptor activity and signaling. Research over the past 20 years has
significantly enhanced our understanding of these regulatory mechanisms and
established an elegant paradigm of GPCR regulation (Moore et al., 2007; DeWire
et al., 2007). However, it is becoming increasingly clear that not all GPCRs fit
this paradigm and a comprehensive analysis of receptor regulation is needed.
Therefore, we investigated the molecular mechanisms that underlie regulation of
GPCR signaling. Specifically, we looked at the roles of the GRKs and arrestins
in regulating signal transduction following activation of two endogenous GPCRs
expressed in HEK293 cells: the M3 mAChR and CXCR4. In addition, using
CXCR4 as a model receptor, we identified agonist-promoted sites of
phosphorylation by mass spectrometry. Using a combination of phospho-specific
antibodies, RNA interference, and specific inhibitors, we then characterized the
kinetics and kinases involved in agonist-promoted phosphorylation. Together,
these studies have significantly enhanced our understanding of CXCR4
regulation and provide the groundwork for understanding dysregulation of
CXCR4 in disease.
Differential Regulation of GPCR-Mediated Signaling Events By GRKs and
Arrestins
The role of GRKs in initiating the process of desensitization is a wellestablished paradigm in GPCR regulation (Krupnick and Benovic, 1998).
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However, emerging evidence has uncovered a previously unappreciated role for
the GRKs and arrestins in initiating G protein-independent signaling cascades
following receptor activation (Reiter and Lefkowitz, 2006). Seminal studies with
the angiotensin and vasopressin receptors have provided evidence for the
following model:

GRK2/3, although primarily responsible for receptor

phosphorylation, negatively regulate arrestin-dependent ERK activation.
Conversely, GRK5/6 play a lesser role in overall receptor phosphorylation, but
positively regulate arrestin-dependent ERK activation (Kim et al., 2005; Ren et
al., 2005). There are two important features implicit in this model: 1) GPCRs are
regulated by numerous GRKs in a coordinated fashion, and 2) GRK-specific
phosphorylation of GPCRs has distinct consequences on receptor activity and
signaling. As similar phenomena have been described for the β2AR (Shenoy SK
et al., 2006) and follicle-stimulating hormone receptor (Kara E et al., 2006), it has
been suggested that this model is applicable to all GPCRs.
As the above-mentioned studies primarily used stable overexpression of
individual receptors, we wanted to better understand how phosphorylation
regulates signaling of endogenous GPCRs. Therefore, we initially analyzed how
siRNA-mediated knock down of the GRKs affected signaling pathways activated
by the M3 mAChR (Gq-coupled) and CXCR4 (Gi-coupled), two receptors
endogenously expressed in HEK293 cells. Using a two-pronged approach of
assaying calcium mobilization and ERK activation, we were able to define and
monitor changes in both the G protein-dependent and –independent signaling
pathways. We found that GRK2, 3, and 6, and arrestin2 and 3 each has a

158

distinct and separable role in regulating the activity of each receptor.
Interestingly, knock down of GRK5 did not effect signaling via either receptor.
Our studies with the M3 mAChR suggest that signaling is strictly through a
G protein-dependent manner and relief of inhibitory constraints (GRKs and
arrestins) subsequently enhances receptor function. In contrast, CXCR4 uses
both a G protein-dependent and –independent (arrestin-dependent) means of
signaling. Intriguingly, and in contrast to previous studies (Kim et al., 2005; Ren
et al., 2005; Kara et al., 2006; Shenoy et al., 2006), G protein-independent
signaling requires both GRK3 and 6, while GRK2 was inhibitory. It is interesting
to note that, to date, GRK2 is largely a negative regulator and GRK6 is largely a
positive regulator of ERK activation. While this is the first demonstration that
GRK2/3 and GRK5/6 cooperate in terms of signaling, it has been recently shown
that GRK2 and 6 are required for the recruitment and high affinity interaction of
arrestin3 with the β2AR (Violin et al., 2006). As more is learned regarding
differences in receptor phosphorylation, the underlying mechanisms should
become apparent.
We have also shown that arrestin2 and 3 differentially regulate the activity
and signaling of CXCR4. Specifically, only knock down of arrestin3 led to
enhanced calcium mobilization following CXCR4 activation, suggesting a loss of
desensitization. In contrast, arrestin2 is primarily responsible for the arrestindependent phase of ERK activation. This apparent reciprocal regulation has
been described for both the angiotensin (Ahn et al., 2004) and PAR1 receptor
(Kuo et al., 2006), where arrestin3 and 2 positively regulated signaling,
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respectively. However, in contrast to the PAR1 receptor (Kuo et al., 2006),
arrestin3 is not completely inhibitory and seems to be required for early activation
of ERK1/2, suggesting a certain degree of codependence (reviewed in DeWire et
al., 2007). In fact, overexpression of arrestin2 and 3 enhances ERK activation of
transiently expressed CXCR4 in HEK293 cells (Cheng et al., 2000).
Interestingly, G protein-dependent and arrestin-dependent signaling are not
temporally distinct (Ahn et al., 2004). How arrestin modulates the subcellular
localization (Luttrell et al., 2001; Tohgo et al., 2002; Ahn et al., 2004) of these
signaling molecules, remains to be seen.
Taken together, these results clearly demonstrate that 1) GPCRs are
dynamically regulated by a number of proteins in a coordinated manner; 2) clear
differences exist between receptors expressed within the same cell type; and 3)
a comprehensive evaluation of individual receptors is needed to truly appreciate
and understand the intricacies of receptor regulation and signaling. One major
limitation of assaying endogenous GPCRs is the inability to directly assess
whether or not the observed effect following GRK knock down is due to a loss of
receptor phosphorylation or through interaction with some downstream signaling
component. This is a critical distinction as the functional consequences of GRKmediated signaling are just beginning to be uncovered.

As we have

demonstrated for the M3 mAChR, using specific point mutants helped delineate
that GRK2 primarily regulated Gαq following receptor activation. As the GRKs
represent important pharmacological targets (Premont RT and Gainetdinov RR,
2007) that interact with a number of proteins (Ribas et al., 2007), the ability to
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specifically target and disrupt these interactions would be a benefit
therapeutically.
Determining Site- and Kinase-Specific Phosphorylation of GPCRs
In order to elucidate a functional role of site- or GRK-specific
phosphorylation, the sites phosphorylated and the kinases involved need to be
determined. Based on our initial studies examining the role of the GRKs in
receptor-mediated signaling, we wanted to further characterize agonist-promoted
phosphorylation of CXCR4. With very few exceptions, the sites of agonistpromoted phosphorylation of GPCRs are largely unknown.

CXCR4 is

extensively phosphorylated on as many as 18 potential phospho-acceptor sites in
the C terminal tail (Haribabu et al, 1997; Orsini et al., 1999). Therefore, in order
to determine agonist-promoted sites of phosphorylation of CXCR4, we needed to
develop a number of biochemical approaches. With the identification of mass
spectrometry-friendly detergents (Cadene et al., 2000) and epitope tag-based
purification (Kobilka 1995), it is now feasible to readily analyze non-visual
GPCRs by mass spectrometry for a myriad of post-translational modifications
(Trester-Zedlitz et al., 2005). Importantly, as has been demonstrated with the
β2AR, differences in receptor phosphorylation clearly exist between in vitro and
“in vivo” studies (Fredericks et al., 1996; Trester-Zedlitz et al., 2005). Therefore,
in an attempt to more closely mimic biologically relevant regulation, we chose to
purify CXCR4 from cell culture.
Mass spectrometry identified 6 sites of phosphorylation following SDFstimulation: Ser321, Ser324, Ser325, one between Ser338-341, and two
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between Ser346-352. Unfortunately, the ability of mass spectrometry to identify
sites of phosphorylation is limited, to a certain degree, by the nature of the
peptides. Using the endopeptidases Lys-C and chymotrypsin, we were able to
generate and identify peptides derived from the C terminal tail and portions of
intracellular loops 2 and 3 of CXCR4. However, a complete complement of
peptides was not observed during the mass spectrometric analysis. Namely,
peptides containing Ser330, the seventh phospho-acceptor site, were not
observed. This demonstrates that a variety of techniques are needed in order to
comprehensively characterize receptor phosphorylation.
Having identified sites of phosphorylation, we next wanted to determine
the kinetics and kinase-specificity of phosphorylation. Therefore, using both the
mass spectrometry results and previous studies (Marchese et al., 2001), we
successfully generated and characterized antibodies directed against pS324/5
and pS330.

Additionally, we were able to use a previously characterized

antibody directed at pS339 (Woerner et al., 2005). These antibodies proved to be
invaluable for identifying and characterizing the kinetics of and kinase-mediated
phosphorylation of CXCR4. Unfortunately, attempts to generate an antibody
directed at pS321, a novel site of phosphorylation, were unsuccessful.
Furthermore, as we were not able to pinpoint the exact residues phosphorylated
between Ser346-352, we were unable to generate antibodies against these
residues.
We have found that GRK6 phosphorylates four serine residues (Ser324/5,
Ser330, and Ser339) and appears to be the kinase primarily responsible for
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CXCR4 phosphorylation. Our data also suggest that GRK3 is responsible for
phosphorylation of two residues between Ser346-352. Finally, we have provided
evidence for a direct and novel role of PKC in agonist-promoted phosphorylation
of CXCR4. Overall, our results are consistent with the C terminal tail acting as
the primary site of phosphorylation (Haribabu et al., 1997). However, we cannot
exclude that residues of the intracellular loops may also be phosphorylated. In
fact, tyrosyl phosphorylation of the first or second intracellular loop has also been
suggested to occur and activate the JAK/STAT pathway independent of G
protein activation (Villa-Coro et al., 1999).

Functional Significance of Site-Specific Phosphorylation of GPCRs
Can a particular functional outcome be directly linked to site-specific
phosphorylation of a GPCR? If so, delineating whether or not certain phosphosites are critical for receptor desensitization, trafficking, and signaling would be of
particular interest. Furthermore, linking individual kinases with site-specific
phosphorylation (and function) would provide significant insight into receptor
regulation and, possibly, a novel area of therapeutic research. To date, the only
comprehensive study linking kinase-specific phosphorylation with a functional
outcome has been with smoothened, a 7 transmembrane receptor closely related
to GPCRs (Zhang et al., 2004; Fredriksson et al., 2003). CXCR4 is of particular
interest as it plays a critical role in diverse physiological processes and is one of
the most commonly expressed receptors found on tumor cells, detected in more
than 20 distinct tumor types (reviewed in Busillo and Benovic, 2007). Here, we
have demonstrated that the GRKs and arrestins differentially regulate activity and
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signaling of CXCR4, providing insight into the functional significance of sitespecific phosphorylation of CXCR4. While these results have direct implications
for CXCR4, the methods developed here are applicable to all GPCRs.
Much of the research on CXCR4 over the past 10 years has focused on
understanding the signaling pathways critical for tumor progression and
metastases (Vandercappellen et al., 2008). Of these pathways, activation of
MAP kinases (i.e., ERK1/2, p38, and JNK) has been linked to cellular migration,
proliferation and survival (reviewed in Kucia et al., 2005). Interestingly, G
protein-dependent and -independent MAP kinase activation are spatially distinct
(Luttrell et al., 2001; Tohgo et al., 2002; Ahn et al., 2004), providing a target of
potential therapeutic intervention. Notably, we have found that GRK3 and 6
positively regulate arrestin-dependent ERK activation. As knock down of GRK6
significantly enhances receptor activity we would predict that targeted disruption
of GRK6 would lead to global enhancement of CXCR4 activity. Conversely,
disrupting GRK3 would be predicted to have no effect on receptor activity while
specifically altering arrestin-dependent ERK activation. However, the differences
between G protein-dependent and –independent signaling downstream of
CXCR4 activation are currently unknown and warrant further investigation.
In addition to the potential importance in signaling, receptor
phosphorylation also drives specific protein/protein interactions, namely with
arrestin2 and 3.

Our results suggest that recruitment of the arrestins is

specifically driven by the differences in receptor phosphorylation, specifically of
residues within the last 15 amino acids of CXCR4. All know WHIM syndrome
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truncations, which significantly enhance receptor function, occur within this
region (Diaz and Gulino, 2005).

Furthermore, deletion of either GRK6 or

arrestin3 in a mouse enhances receptor function (Fong et al., 2002). Consistent
with these observations, knock down of GRK6 and arrestin3 significantly
enhances calcium mobilization. Of the 4 sites phosphorylated by GRK6, Ser339
occurs the quickest, peaking within 2 minutes of stimulation.

Moreover,

overexpression of arrestin3 is unable to rescue desensitization and
internalization of CXCR4 lacking the last 15 amino acids (Balabanian et al.,
2008).

Collectively, based on these results, we could hypothesize that

phosphorylation of Ser339 is responsible for the initial recruitment of arrestin3 to
CXCR4. Notably, GRK6 phosphorylation is also primarily responsible for the
recruitment of arrestin3 to the β2AR in HEK293 cells (Violin et al., 2006). On the
other hand, the interaction of arrestin2 with CXCR4 appears to be driven by
GRK6- and GRK3-mediated phosphorylation of Ser 330 and Ser339 and Ser346352, respectively. However, it is important to note that we were unable to
determine the kinetics of GRK3-mediated phosphorylation of Ser346-352.
Intriguingly, PKC-mediated phosphorylation of Ser324/5, though robust,
does not appear to contribute to either the recruitment of arrestin or G proteinindependent signaling. Given the critical role of these residues in receptor
degradation (Marchese and Benovic, 2001), it is reasonable to hypothesize that
PKC-mediated phosphorylation drives receptor degradation. In fact,
phosphorylation of Ser324/5 appears to be required for the interaction of AIP4
with CXCR4 and subsequent receptor ubiquitination (A. Marchese, personal
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communication). Accordingly, preliminary studies have suggested that PKC
inhibition is sufficient to completely block receptor degradation (data not shown).
Additionally, arrestin2 interacts with both CXCR4 and AIP4 at the endosome,
directing CXCR4 into the degradative pathway (Bhandari et al., 2007). This
interaction could be largely driven/stabilized by phosphorylation of Ser330, which
we found to peak between 10 and 20 min of SDF-stimulation.
A conservative estimate puts GPCRs as targets for ~30% of currently
marketed pharmaceutical drugs (Jacoby et al., 2006). The overall significance of
the research presented here, and linking site-specific phosphorylation to a
functional outcome in general, will have a broad impact on both basic and clinical
research. For CXCR4 specifically, we can now begin to address the functional
role of site- and kinase-specific phosphorylation of CXCR4 in a variety of tissues.
More importantly, we can also begin to have a better understanding of whether or
not there is altered regulation of CXCR4 in a variety of diseases. It is clear that
from the work presented here that CXCR4 phosphorylation is not just an off
switch for receptor activity, but in fact drives signaling pathways and likely a
variety of protein-protein interactions. How these pathways are integrated in vivo
presents a significant, but interesting challenge for future research.

Future Directions
The work presented here has significantly enhanced our current
understanding of the mechanisms regulating CXCR4 activity and signaling.
However, despite these advances, additional biochemical and cellular studies are
warranted to further expand on the novel insights gained here.
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One of the novel findings of the research presented in this thesis was the
demonstration that individual kinases phosphorylate distinct sites on CXCR4. It
is expected that receptor regulation and site-specific phosphorylation would
largely depend on tissue-specific differences in protein expression. In fact, cell
type-dependent phosphorylation has been noted for the M3 mAChR (Torrecilla et
al., 2007). Importantly, these studies revealed both common and cell typespecific sites of phosphorylation (Torrecilla et al., 2007). Using the phosphospecific antibodies described here will allow us to quickly assess site-specific
phosphorylation in a variety of tissues. Furthermore, and of substantial interest,
these could be used to determine if kinase-specificity is conserved in tissues and
tumors or is it a result of the relative expression of the individual GRKs (Violin et
al., 2006).
Our data show a direct, and novel role for PKC as the primary kinase
responsible for agonist-promoted phosphorylation of Ser324/5. Determining to
what extent PKC is involved in Ser324/5 phosphorylation in a variety of tissues
would help substantiate our findings. Furthermore, preliminary results suggest
that PKC is critically involved in regulating CXCR4 degradation. Inhibition of
PKC significantly blocks agonist-promoted degradation of CXCR4, however, we
are currently unable to distinguish if this is due to alterations in receptor
trafficking, ubiquitination, or combination of the two. Extensive studies examining
cellular localization and receptor ubiquitination are warranted to fully delineate
how PKC, and to a larger extent Ser324/5 phosphorylation, affects receptor
degradation.
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We have observed that phosphorylation of CXCR4 occurs with clear
kinetic differences. However, in the experiments presented here, we have not
fully addressed the biological relevance of this. Our current hypothesis is that
phosphorylation of Ser339 is critical for arrestin3 recruitment, while
phosphorylation of Ser330, Ser339, and Ser346-352 are critical for forming a
stable arrestin2/CXCR4 complex. In order to address arrestin recruitment and
interaction, we are currently investigating whether CXCR4 results in a
conformational change of arrestin2 and 3 by intramolecular bioluminescent
energy transfer (BRET) (Charest et al., 2005). These studies should additionally
provide both the kinetics and the relative stability of arrestin recruitment and
interaction with CXCR4, respectively. If positive, these studies would then be
expanded to look at how the knock down of GRK3 and GRK6 and specific
receptor point mutants affect these parameters. Furthermore, detailed cellular
localization studies using individual point mutants would provide further functional
insight into site-specific phosphorylation.
How the GRKs and arrestins contribute to cancer progression and
metastases in CXCR4-positive tumors is also of significant interest. Specifically,
what arrestin-dependent signaling pathways are activated that contribute to
cancer progression and metastases of these tumors? Interestingly, to date there
have been no studies describing cancer progression/metastases in patients with
WHIM syndrome. All of the WHIM mutations described to date either truncate
the last 10-15 amino acids of CXCR4 or have selective loss of GRK3 (Diaz and
Gulino, 2005; Balabanian et al., 2008), which we would predict are critical for
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activation of arrestin2-dependent signaling.

A simple way to address this

question would be to compare the signaling pathways activated downstream of
wild type or C terminally truncated (to Ser338) CXCR4 by western blot or
microarray analysis. Given the clear role of arrestins in G protein-independent
signaling and the recent demonstration that arrestin directly regulates gene
transcription (Kang et al., 2005), it would be interesting to study how CXCR4
affecs the subcellular localization of arrestin following activation.
Immunohistochemical studies analyzing the expression pattern of arrestin in
breast cancer tissue have been initiated in the laboratory. Using a similar
approach for the individual GRKs could provide correlations between CXCR4
expression and any alterations in the levels of the GRKs.
Finally, we have described an efficient and rapid protocol for purifying
activated, phosphorylated CXCR4. Using this protocol, it may be possible to
determine proteins that specifically interact with CXCR4 in an agonsit-dependent
manner.

However, it should be noted that the relative affinities of these

interactions may be weak and would need experimental manipulation (i.e.,
chemical crosslinking) to maintain.

Additionally, with further optimization,

activated phosphorylated CXCR4 may be purified to sufficient homogeneity to
allow for crystallization and structural determination.

To date, the crystal

structures of a handful of GPCRs have been solved (Palczewski et al., 2001;
Cherezov et al., 2007; Rasmussen et al., 2007; Jaakola et al., 2008; Park et al.,
2008). Each of these structures has had a substantial impact, however with the
exception of metarhodopsin (Park et al., 2008), they are inactive and, for some,
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are chimeras that allowed for receptor stabilization and crystallization (Cherezov
et al., 2007; Jaakola et al., 2008). While undoubtedly a daunting task, the
possibility of obtaining a crystal structure of a GPCR in its active form, and
possibly complexed with other proteins (e.g., G proteins or arrestin), would be a
significant revelation for the field of GPCR biology.
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